https://trial.medpath.com/news/roche-invests-300-million-in-new-shanghai-biologics-manufacturing-facility 2025-05-12T16:45:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-invests-300-million-in-new-shanghai-biologics-manufacturing-facility 2025-05-12T16:45:21+00:00 hourly 0.9 https://trial.medpath.com/news/n4-pharma-reports-positive-results-from-first-in-vivo-study-of-nuvec-r-for-inflammatory-bowel-disease 2025-05-12T16:44:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/n4-pharma-reports-positive-results-from-first-in-vivo-study-of-nuvec-r-for-inflammatory-bowel-disease 2025-05-12T16:44:43+00:00 hourly 0.9 https://trial.medpath.com/news/esperion-secures-patent-protection-for-nexletol-until-2040-through-settlement-with-micro-labs 2025-05-12T16:44:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperion-secures-patent-protection-for-nexletol-until-2040-through-settlement-with-micro-labs 2025-05-12T16:44:37+00:00 hourly 0.9 https://trial.medpath.com/news/synact-pharma-secures-extended-us-patent-protection-for-resomelagon-combination-therapy-until-2042 2025-05-12T16:44:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synact-pharma-secures-extended-us-patent-protection-for-resomelagon-combination-therapy-until-2042 2025-05-12T16:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/orthotrophix-launches-phase-2b-trial-of-tpx-100-for-knee-osteoarthritis-with-disease-modifying-potential 2025-05-12T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orthotrophix-launches-phase-2b-trial-of-tpx-100-for-knee-osteoarthritis-with-disease-modifying-potential 2025-05-12T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-strengthens-regulatory-team-ahead-of-critical-phase-3-trials-and-nda-submission 2025-05-12T16:42:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-strengthens-regulatory-team-ahead-of-critical-phase-3-trials-and-nda-submission 2025-05-12T16:42:28+00:00 hourly 0.9 https://trial.medpath.com/news/bioxytran-achieves-critical-milestone-in-prolectin-m-antiviral-development 2025-05-12T16:42:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxytran-achieves-critical-milestone-in-prolectin-m-antiviral-development 2025-05-12T16:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-mavrix-bio-s-gene-therapy-for-angelman-syndrome-first-in-human-trial-to-begin-in-2025 2025-05-12T16:41:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-mavrix-bio-s-gene-therapy-for-angelman-syndrome-first-in-human-trial-to-begin-in-2025 2025-05-12T16:41:57+00:00 hourly 0.9 https://trial.medpath.com/news/quidditas-secures-eur2-62m-to-advance-revolutionary-genome-editing-technology-for-rare-disease-treatment 2025-05-12T16:41:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidditas-secures-eur2-62m-to-advance-revolutionary-genome-editing-technology-for-rare-disease-treatment 2025-05-12T16:41:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-capsida-s-revolutionary-iv-gene-therapy-for-stxbp1-dee-first-to-cross-blood-brain-barrier 2025-05-12T16:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-capsida-s-revolutionary-iv-gene-therapy-for-stxbp1-dee-first-to-cross-blood-brain-barrier 2025-05-12T16:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/omeros-restructures-80-5-million-in-debt-significantly-reducing-near-term-financial-obligations 2025-05-12T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omeros-restructures-80-5-million-in-debt-significantly-reducing-near-term-financial-obligations 2025-05-12T16:40:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-ensoma-s-first-in-class-in-vivo-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-05-12T16:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-ensoma-s-first-in-class-in-vivo-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-05-12T16:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/andelyn-biosciences-delivers-breakthrough-gene-therapy-for-ultra-rare-nedamss-disease-in-record-time 2025-05-12T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andelyn-biosciences-delivers-breakthrough-gene-therapy-for-ultra-rare-nedamss-disease-in-record-time 2025-05-12T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-funding-surges-to-141-2-billion-as-industry-expands-globally 2025-05-12T16:40:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-funding-surges-to-141-2-billion-as-industry-expands-globally 2025-05-12T16:40:45+00:00 hourly 0.9 https://trial.medpath.com/news/igc-pharma-s-alzheimer-s-drug-igc-ad1-passes-critical-genetic-safety-test 2025-05-12T16:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/igc-pharma-s-alzheimer-s-drug-igc-ad1-passes-critical-genetic-safety-test 2025-05-12T16:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-targeted-therapy-for-igg4-related-disease-amgen-s-uplizna 2025-05-12T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-targeted-therapy-for-igg4-related-disease-amgen-s-uplizna 2025-05-12T16:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/curaleaf-international-secures-eu-medical-device-certification-for-pioneering-cannabis-inhalation-technology 2025-05-12T16:17:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curaleaf-international-secures-eu-medical-device-certification-for-pioneering-cannabis-inhalation-technology 2025-05-12T16:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-to-invest-700-million-in-new-north-carolina-manufacturing-facility-creating-400-high-paying-jobs 2025-05-12T16:15:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-to-invest-700-million-in-new-north-carolina-manufacturing-facility-creating-400-high-paying-jobs 2025-05-12T16:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/nextgen-jane-secures-2-2m-nih-grant-to-validate-non-invasive-endometriosis-diagnostic 2025-05-12T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextgen-jane-secures-2-2m-nih-grant-to-validate-non-invasive-endometriosis-diagnostic 2025-05-12T16:15:46+00:00 hourly 0.9 https://trial.medpath.com/news/grit-biotechnology-to-present-breakthrough-immunotherapy-advances-at-asgct-2025 2025-05-12T16:15:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grit-biotechnology-to-present-breakthrough-immunotherapy-advances-at-asgct-2025 2025-05-12T16:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/true-indicating-secures-fda-clearance-for-cspn-15-steam-sterilization-monitoring-device 2025-05-12T16:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/true-indicating-secures-fda-clearance-for-cspn-15-steam-sterilization-monitoring-device 2025-05-12T16:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/vgxi-s-successful-fda-inspection-leads-to-client-s-bla-approval-strengthening-position-in-plasmid-dna-manufacturing 2025-05-12T16:15:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vgxi-s-successful-fda-inspection-leads-to-client-s-bla-approval-strengthening-position-in-plasmid-dna-manufacturing 2025-05-12T16:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/inbrain-pharma-secures-eur1-8-million-to-industrialize-anaerobic-dopamine-production-for-advanced-parkinson-s-disease 2025-05-12T16:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inbrain-pharma-secures-eur1-8-million-to-industrialize-anaerobic-dopamine-production-for-advanced-parkinson-s-disease 2025-05-12T16:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/ubrogepant-shows-promise-in-treating-migraine-prodromal-symptoms-in-phase-iii-trial 2025-05-12T16:13:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubrogepant-shows-promise-in-treating-migraine-prodromal-symptoms-in-phase-iii-trial 2025-05-12T16:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/36-month-results-of-opregen-cell-therapy-for-geographic-atrophy-to-be-presented-at-cts-2025 2025-05-12T16:13:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/36-month-results-of-opregen-cell-therapy-for-geographic-atrophy-to-be-presented-at-cts-2025 2025-05-12T16:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-alzheimer-s-drug-lecanemab-shows-manageable-safety-profile-in-real-world-setting 2025-05-12T16:13:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-alzheimer-s-drug-lecanemab-shows-manageable-safety-profile-in-real-world-setting 2025-05-12T16:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/intrepid-labs-emerges-from-stealth-with-ai-powered-platform-to-revolutionize-drug-formulation 2025-05-12T14:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrepid-labs-emerges-from-stealth-with-ai-powered-platform-to-revolutionize-drug-formulation 2025-05-12T14:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/veradigm-deploys-ai-to-extract-real-world-insights-on-glp-1-medications-from-ehr-data 2025-05-12T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veradigm-deploys-ai-to-extract-real-world-insights-on-glp-1-medications-from-ehr-data 2025-05-12T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/aura-and-life360-form-25-million-strategic-partnership-for-family-safety-solutions 2025-05-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aura-and-life360-form-25-million-strategic-partnership-for-family-safety-solutions 2025-05-12T14:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-1273-covid-19-vaccine-shows-promise-in-phase-1-trial-advances-to-phase-3-testing 2025-05-12T12:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-1273-covid-19-vaccine-shows-promise-in-phase-1-trial-advances-to-phase-3-testing 2025-05-12T12:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/india-rejects-uk-s-data-exclusivity-demand-to-protect-25-billion-generic-drug-industry 2025-05-12T12:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-rejects-uk-s-data-exclusivity-demand-to-protect-25-billion-generic-drug-industry 2025-05-12T12:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/chong-kun-dang-invests-w10-billion-in-abclon-to-advance-car-t-and-antibody-therapies 2025-05-12T12:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chong-kun-dang-invests-w10-billion-in-abclon-to-advance-car-t-and-antibody-therapies 2025-05-12T12:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-s-cx-2051-shows-promising-28-response-rate-in-advanced-colorectal-cancer-phase-1-trial 2025-05-12T12:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-s-cx-2051-shows-promising-28-response-rate-in-advanced-colorectal-cancer-phase-1-trial 2025-05-12T12:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-purdue-university-forge-250-million-partnership-to-accelerate-pharmaceutical-innovation 2025-05-12T12:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-purdue-university-forge-250-million-partnership-to-accelerate-pharmaceutical-innovation 2025-05-12T12:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/new-transcatheter-tricuspid-valve-treatments-offer-hope-for-high-risk-cardiac-patients 2025-05-12T12:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-transcatheter-tricuspid-valve-treatments-offer-hope-for-high-risk-cardiac-patients 2025-05-12T12:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/thermosome-s-the001-receives-fda-orphan-drug-designation-for-soft-tissue-sarcoma-treatment 2025-05-12T12:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermosome-s-the001-receives-fda-orphan-drug-designation-for-soft-tissue-sarcoma-treatment 2025-05-12T12:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/orca-bio-appoints-co-founder-nate-fernhoff-as-ceo-ahead-of-2025-bla-submission-for-orca-t 2025-05-12T11:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orca-bio-appoints-co-founder-nate-fernhoff-as-ceo-ahead-of-2025-bla-submission-for-orca-t 2025-05-12T11:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/zynex-submits-fda-application-for-nico-revolutionary-laser-pulse-oximeter-addresses-racial-bias-in-patient-monitoring 2025-05-12T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zynex-submits-fda-application-for-nico-revolutionary-laser-pulse-oximeter-addresses-racial-bias-in-patient-monitoring 2025-05-12T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/alligator-bioscience-to-present-biomarker-data-from-promising-pancreatic-cancer-trial-at-asco-2025 2025-05-12T08:40:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alligator-bioscience-to-present-biomarker-data-from-promising-pancreatic-cancer-trial-at-asco-2025 2025-05-12T08:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-once-weekly-sogroya-shows-efficacy-in-children-with-growth-disorders-in-phase-3-trial 2025-05-12T08:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-once-weekly-sogroya-shows-efficacy-in-children-with-growth-disorders-in-phase-3-trial 2025-05-12T08:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-trixeo-aerosphere-becomes-first-inhaled-respiratory-medicine-with-near-zero-climate-impact-propellant 2025-05-12T08:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-trixeo-aerosphere-becomes-first-inhaled-respiratory-medicine-with-near-zero-climate-impact-propellant 2025-05-12T08:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/leucid-bio-doses-first-patient-in-aerial-trial-of-novel-nkg2d-car-t-therapy-for-solid-tumors 2025-05-12T08:39:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leucid-bio-doses-first-patient-in-aerial-trial-of-novel-nkg2d-car-t-therapy-for-solid-tumors 2025-05-12T08:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/valirx-expands-precision-oncology-partnership-with-dominion-biotech-through-predictrx-platform-licensing 2025-05-12T08:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valirx-expands-precision-oncology-partnership-with-dominion-biotech-through-predictrx-platform-licensing 2025-05-12T08:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/metis-pharmaceuticals-plans-200-million-hong-kong-ipo-to-advance-ai-driven-drug-development 2025-05-12T08:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-pharmaceuticals-plans-200-million-hong-kong-ipo-to-advance-ai-driven-drug-development 2025-05-12T08:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-aqilion-s-ind-application-for-aq280-in-eosinophilic-esophagitis-treatment 2025-05-12T08:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-aqilion-s-ind-application-for-aq280-in-eosinophilic-esophagitis-treatment 2025-05-12T08:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/vuno-s-ai-powered-cardiac-arrest-prediction-system-secures-ce-mdr-and-ukca-certifications 2025-05-12T08:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vuno-s-ai-powered-cardiac-arrest-prediction-system-secures-ce-mdr-and-ukca-certifications 2025-05-12T08:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/synthego-launches-gmp-spcas9-to-streamline-crispr-therapeutic-development 2025-05-12T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthego-launches-gmp-spcas9-to-streamline-crispr-therapeutic-development 2025-05-12T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/agenus-reports-breakthrough-response-rates-for-bot-bal-combination-in-cold-tumors 2025-05-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agenus-reports-breakthrough-response-rates-for-bot-bal-combination-in-cold-tumors 2025-05-12T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/former-j-j-executive-herwig-janssen-appointed-chairman-of-tryptamine-therapeutics-as-company-advances-psilocin-based-clinical-programs 2025-05-12T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-j-j-executive-herwig-janssen-appointed-chairman-of-tryptamine-therapeutics-as-company-advances-psilocin-based-clinical-programs 2025-05-12T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/radiopharm-theranostics-advances-phase-1-trial-of-pd-l1-targeting-radiotherapeutic-for-advanced-cancers 2025-05-12T04:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiopharm-theranostics-advances-phase-1-trial-of-pd-l1-targeting-radiotherapeutic-for-advanced-cancers 2025-05-12T04:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-allogeneic-bcma-car-t-shows-promising-safety-and-efficacy-in-relapsed-refractory-multiple-myeloma 2025-05-12T04:38:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-allogeneic-bcma-car-t-shows-promising-safety-and-efficacy-in-relapsed-refractory-multiple-myeloma 2025-05-12T04:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-mesutoclax-receives-breakthrough-therapy-designation-in-china-for-lymphoma-treatment 2025-05-12T04:08:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-mesutoclax-receives-breakthrough-therapy-designation-in-china-for-lymphoma-treatment 2025-05-12T04:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/nanoscope-therapeutics-showcases-mco-010-optogenetic-therapy-data-at-asgct-2025 2025-05-12T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoscope-therapeutics-showcases-mco-010-optogenetic-therapy-data-at-asgct-2025 2025-05-12T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/weight-loss-injections-show-promising-anti-cancer-effects-beyond-weight-reduction 2025-05-12T02:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-loss-injections-show-promising-anti-cancer-effects-beyond-weight-reduction 2025-05-12T02:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/denosumab-shows-immunomodulatory-effects-in-her2-negative-early-breast-cancer 2025-05-12T00:34:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denosumab-shows-immunomodulatory-effects-in-her2-negative-early-breast-cancer 2025-05-12T00:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/wehi-3773-small-molecule-shows-promise-for-blocking-cell-death-in-neurodegenerative-diseases 2025-05-12T00:34:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wehi-3773-small-molecule-shows-promise-for-blocking-cell-death-in-neurodegenerative-diseases 2025-05-12T00:34:20+00:00 hourly 0.9 https://trial.medpath.com/news/united-healthcare-approves-reimbursement-for-helius-medical-s-pons-device-for-ms-patients 2025-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-healthcare-approves-reimbursement-for-helius-medical-s-pons-device-for-ms-patients 2025-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tobin-scientific-secures-65m-investment-to-expand-life-sciences-infrastructure-and-services 2025-05-11T20:39:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tobin-scientific-secures-65m-investment-to-expand-life-sciences-infrastructure-and-services 2025-05-11T20:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-arabia-seeks-to-localize-insulin-and-glp-1-production-through-novo-nordisk-partnership 2025-05-11T20:39:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saudi-arabia-seeks-to-localize-insulin-and-glp-1-production-through-novo-nordisk-partnership 2025-05-11T20:39:43+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-acquires-esobiotec-for-1-billion-revolutionary-in-vivo-car-t-technology-to-transform-cancer-treatment 2025-05-11T20:39:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-acquires-esobiotec-for-1-billion-revolutionary-in-vivo-car-t-technology-to-transform-cancer-treatment 2025-05-11T20:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/type-2-diabetes-significantly-increases-risk-of-mash-progression-to-cirrhosis-new-target-rwe-study-reveals 2025-05-11T17:36:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/type-2-diabetes-significantly-increases-risk-of-mash-progression-to-cirrhosis-new-target-rwe-study-reveals 2025-05-11T17:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/lorlatinib-shows-impressive-5-year-pfs-results-in-alk-positive-advanced-nsclc 2025-05-11T16:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lorlatinib-shows-impressive-5-year-pfs-results-in-alk-positive-advanced-nsclc 2025-05-11T16:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/inductive-bio-secures-25m-series-a-to-revolutionize-small-molecule-drug-discovery-with-ai 2025-05-11T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inductive-bio-secures-25m-series-a-to-revolutionize-small-molecule-drug-discovery-with-ai 2025-05-11T16:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/tfox-regimen-shows-superior-efficacy-over-folfox-in-advanced-her2-negative-gastric-cancer 2025-05-11T16:38:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tfox-regimen-shows-superior-efficacy-over-folfox-in-advanced-her2-negative-gastric-cancer 2025-05-11T16:38:34+00:00 hourly 0.9 https://trial.medpath.com/news/givinostat-shows-promise-for-duchenne-muscular-dystrophy-as-families-push-for-broader-access 2025-05-11T16:10:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/givinostat-shows-promise-for-duchenne-muscular-dystrophy-as-families-push-for-broader-access 2025-05-11T16:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/innovative-hydrogel-technologies-transform-chronic-wound-treatment-with-enhanced-healing-properties 2025-05-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovative-hydrogel-technologies-transform-chronic-wound-treatment-with-enhanced-healing-properties 2025-05-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glass-house-brands-partners-with-uc-berkeley-for-groundbreaking-hemp-research-initiative 2025-05-11T12:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glass-house-brands-partners-with-uc-berkeley-for-groundbreaking-hemp-research-initiative 2025-05-11T12:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/abcellera-s-abcl575-shows-promise-for-atopic-dermatitis-with-extended-half-life-in-preclinical-studies 2025-05-11T12:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcellera-s-abcl575-shows-promise-for-atopic-dermatitis-with-extended-half-life-in-preclinical-studies 2025-05-11T12:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/sivec-s-bactpac-platform-engineered-bacteria-redefining-targeted-drug-delivery-for-cancer-and-beyond 2025-05-11T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sivec-s-bactpac-platform-engineered-bacteria-redefining-targeted-drug-delivery-for-cancer-and-beyond 2025-05-11T08:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-signs-agreement-to-access-russia-s-potential-mrna-cancer-vaccine 2025-05-11T04:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-signs-agreement-to-access-russia-s-potential-mrna-cancer-vaccine 2025-05-11T04:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/omada-health-files-for-ipo-showcasing-strong-growth-in-virtual-chronic-care-market 2025-05-11T03:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omada-health-files-for-ipo-showcasing-strong-growth-in-virtual-chronic-care-market 2025-05-11T03:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-announces-150-million-capital-expenditure-plan-amid-strong-q4-performance 2025-05-11T00:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-announces-150-million-capital-expenditure-plan-amid-strong-q4-performance 2025-05-11T00:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-and-apiject-partner-to-expand-us-based-sterile-injectable-manufacturing-with-advanced-bfs-technology 2025-05-11T00:34:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-and-apiject-partner-to-expand-us-based-sterile-injectable-manufacturing-with-advanced-bfs-technology 2025-05-11T00:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/kouper-emerges-from-stealth-with-10m-to-transform-hospital-discharge-care-transitions 2025-05-11T00:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kouper-emerges-from-stealth-with-10m-to-transform-hospital-discharge-care-transitions 2025-05-11T00:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-study-identifies-key-immune-defects-limiting-pancreatic-cancer-immunotherapy-response 2025-05-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-study-identifies-key-immune-defects-limiting-pancreatic-cancer-immunotherapy-response 2025-05-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytel-and-nested-knowledge-partner-to-revolutionize-ai-enhanced-systematic-literature-reviews-for-healthcare-economics 2025-05-10T23:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytel-and-nested-knowledge-partner-to-revolutionize-ai-enhanced-systematic-literature-reviews-for-healthcare-economics 2025-05-10T23:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/adma-biologics-secures-fda-clearance-for-yield-enhancement-process-poised-for-margin-expansion-in-2026 2025-05-10T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adma-biologics-secures-fda-clearance-for-yield-enhancement-process-poised-for-margin-expansion-in-2026 2025-05-10T21:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/nanyang-biologics-and-precisya-global-form-strategic-alliance-to-advance-ai-driven-natural-compound-discovery 2025-05-10T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanyang-biologics-and-precisya-global-form-strategic-alliance-to-advance-ai-driven-natural-compound-discovery 2025-05-10T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-novartis-protocol-amendment-for-iptacopan-study-in-rare-kidney-disorders 2025-05-10T20:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-novartis-protocol-amendment-for-iptacopan-study-in-rare-kidney-disorders 2025-05-10T20:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/eyp-1901-shows-promising-results-in-verona-trial-for-diabetic-macular-edema 2025-05-10T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyp-1901-shows-promising-results-in-verona-trial-for-diabetic-macular-edema 2025-05-10T20:10:20+00:00 hourly 0.9 https://trial.medpath.com/news/hku-researchers-develop-breakthrough-needle-free-flu-vaccine-with-broader-protection 2025-05-10T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hku-researchers-develop-breakthrough-needle-free-flu-vaccine-with-broader-protection 2025-05-10T20:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/clemson-researchers-test-existing-drugs-for-sanfilippo-syndrome-using-fruit-fly-models 2025-05-10T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clemson-researchers-test-existing-drugs-for-sanfilippo-syndrome-using-fruit-fly-models 2025-05-10T18:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/healthy-extracts-secures-exclusive-rights-to-innovative-nutrient-infused-straw-technology 2025-05-10T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthy-extracts-secures-exclusive-rights-to-innovative-nutrient-infused-straw-technology 2025-05-10T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-dna-successfully-controls-gene-expression-in-mammalian-cells-for-first-time 2025-05-10T17:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-dna-successfully-controls-gene-expression-in-mammalian-cells-for-first-time 2025-05-10T17:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-ecog-acrin-ea4151-trial-evaluates-necessity-of-auto-hct-in-modern-mcl-treatment 2025-05-10T16:35:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-ecog-acrin-ea4151-trial-evaluates-necessity-of-auto-hct-in-modern-mcl-treatment 2025-05-10T16:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/helios-trial-shows-promise-otx-tki-demonstrates-positive-results-for-diabetic-retinopathy-treatment 2025-05-10T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helios-trial-shows-promise-otx-tki-demonstrates-positive-results-for-diabetic-retinopathy-treatment 2025-05-10T16:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/skyline-therapeutics-to-present-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025 2025-05-10T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skyline-therapeutics-to-present-novel-optogenetic-gene-therapy-for-retinitis-pigmentosa-at-asgct-2025 2025-05-10T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/lithuanian-firm-delta-biosciences-to-launch-pioneering-space-pharmaceutical-stability-study-on-iss 2025-05-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lithuanian-firm-delta-biosciences-to-launch-pioneering-space-pharmaceutical-stability-study-on-iss 2025-05-10T16:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/hawaii-secures-700-million-settlement-from-bristol-myers-squibb-and-sanofi-over-plavix-efficacy-in-diverse-populations 2025-05-10T15:11:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hawaii-secures-700-million-settlement-from-bristol-myers-squibb-and-sanofi-over-plavix-efficacy-in-diverse-populations 2025-05-10T15:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/scg101-shows-dual-antiviral-and-antitumor-effects-in-hbv-related-liver-cancer-trial 2025-05-10T15:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scg101-shows-dual-antiviral-and-antitumor-effects-in-hbv-related-liver-cancer-trial 2025-05-10T15:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-partners-with-qure-ai-to-advance-ai-powered-lung-cancer-detection-in-india 2025-05-10T13:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-partners-with-qure-ai-to-advance-ai-powered-lung-cancer-detection-in-india 2025-05-10T13:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/trailhead-biosystems-secures-20m-to-advance-ipsc-technology-for-drug-discovery-and-regenerative-medicine 2025-05-10T12:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trailhead-biosystems-secures-20m-to-advance-ipsc-technology-for-drug-discovery-and-regenerative-medicine 2025-05-10T12:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/thirona-and-copd-foundation-launch-major-ai-study-to-transform-copd-treatment 2025-05-10T12:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thirona-and-copd-foundation-launch-major-ai-study-to-transform-copd-treatment 2025-05-10T12:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/aflibercept-8-mg-shows-extended-dosing-intervals-in-real-world-namd-treatment 2025-05-10T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aflibercept-8-mg-shows-extended-dosing-intervals-in-real-world-namd-treatment 2025-05-10T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/global-diabetes-care-market-projected-to-reach-62-73-billion-by-2032-driven-by-rising-disease-prevalence-and-technology-advances 2025-05-10T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-diabetes-care-market-projected-to-reach-62-73-billion-by-2032-driven-by-rising-disease-prevalence-and-technology-advances 2025-05-10T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/ngex-minerals-reports-exceptional-gold-grades-in-phase-3-drilling-at-lunahuasi-project 2025-05-10T08:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ngex-minerals-reports-exceptional-gold-grades-in-phase-3-drilling-at-lunahuasi-project 2025-05-10T08:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/lumithera-s-valeda-light-delivery-system-shows-extended-vision-benefits-in-dry-amd-patients-over-4-5-years 2025-05-10T07:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumithera-s-valeda-light-delivery-system-shows-extended-vision-benefits-in-dry-amd-patients-over-4-5-years 2025-05-10T07:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/nelipak-expands-healthcare-packaging-operations-in-costa-rica-with-new-60m-manufacturing-facility 2025-05-10T07:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nelipak-expands-healthcare-packaging-operations-in-costa-rica-with-new-60m-manufacturing-facility 2025-05-10T07:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-demands-additional-trial-for-novavax-covid-19-vaccine-delaying-full-approval 2025-05-10T04:39:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-demands-additional-trial-for-novavax-covid-19-vaccine-delaying-full-approval 2025-05-10T04:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/aprocitentan-shows-promising-results-in-black-adults-with-resistant-hypertension 2025-05-10T04:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprocitentan-shows-promising-results-in-black-adults-with-resistant-hypertension 2025-05-10T04:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/avammune-therapeutics-secures-12m-series-a-funding-to-advance-novel-cancer-immunotherapy 2025-05-10T04:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avammune-therapeutics-secures-12m-series-a-funding-to-advance-novel-cancer-immunotherapy 2025-05-10T04:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/lumithera-s-valeda-light-delivery-system-shows-sustained-vision-improvement-in-dry-amd-patients 2025-05-10T04:38:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumithera-s-valeda-light-delivery-system-shows-sustained-vision-improvement-in-dry-amd-patients 2025-05-10T04:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/tarlatamab-shows-superior-survival-in-small-cell-lung-cancer-key-highlights-from-asco-2025 2025-05-10T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarlatamab-shows-superior-survival-in-small-cell-lung-cancer-key-highlights-from-asco-2025 2025-05-10T04:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/braf-p-v600e-mutation-shows-limited-prognostic-value-in-papillary-thyroid-cancer-risk-stratification 2025-05-10T03:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/braf-p-v600e-mutation-shows-limited-prognostic-value-in-papillary-thyroid-cancer-risk-stratification 2025-05-10T03:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-sequencing-of-t-cell-therapies-in-relapsed-refractory-multiple-myeloma-expert-guidelines 2025-05-10T02:41:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-sequencing-of-t-cell-therapies-in-relapsed-refractory-multiple-myeloma-expert-guidelines 2025-05-10T02:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/taysha-gene-therapies-advances-tsha-102-for-rett-syndrome-with-fda-alignment-on-pivotal-trial-design 2025-05-10T02:40:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taysha-gene-therapies-advances-tsha-102-for-rett-syndrome-with-fda-alignment-on-pivotal-trial-design 2025-05-10T02:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/reduced-dose-radiotherapy-shows-promise-for-early-stage-anal-cancer-treatment 2025-05-10T02:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reduced-dose-radiotherapy-shows-promise-for-early-stage-anal-cancer-treatment 2025-05-10T02:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/new-cancer-center-at-jfk-university-medical-center-aims-to-enhance-multidisciplinary-care 2025-05-10T02:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-cancer-center-at-jfk-university-medical-center-aims-to-enhance-multidisciplinary-care 2025-05-10T02:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-treatment-strategies-for-epithelioid-sarcoma-from-frontline-approaches-to-disease-progression-management 2025-05-10T02:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-treatment-strategies-for-epithelioid-sarcoma-from-frontline-approaches-to-disease-progression-management 2025-05-10T02:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/newbiologix-licenses-high-yield-hek293-cell-line-to-recibiopharm-for-advanced-aav-gene-therapy-production 2025-05-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newbiologix-licenses-high-yield-hek293-cell-line-to-recibiopharm-for-advanced-aav-gene-therapy-production 2025-05-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-funding-crisis-forces-strategic-pivots-as-vc-investment-remains-challenging-despite-recovery-signs 2025-05-10T01:03:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-funding-crisis-forces-strategic-pivots-as-vc-investment-remains-challenging-despite-recovery-signs 2025-05-10T01:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-accelerates-us-investment-strategy-while-advancing-three-pivotal-phase-iii-programs-for-2025 2025-05-10T00:40:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-accelerates-us-investment-strategy-while-advancing-three-pivotal-phase-iii-programs-for-2025 2025-05-10T00:40:11+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-als-treatment-canadian-researchers-successfully-bypass-blood-brain-barrier 2025-05-10T00:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-als-treatment-canadian-researchers-successfully-bypass-blood-brain-barrier 2025-05-10T00:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/coave-therapeutics-unveils-coaav-csf-01-a-breakthrough-gene-therapy-vector-for-cns-diseases 2025-05-10T00:39:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coave-therapeutics-unveils-coaav-csf-01-a-breakthrough-gene-therapy-vector-for-cns-diseases 2025-05-10T00:39:20+00:00 hourly 0.9 https://trial.medpath.com/news/plozasiran-shows-promise-in-reducing-cholesterol-and-triglycerides-in-mixed-hyperlipidemia-patients 2025-05-10T00:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plozasiran-shows-promise-in-reducing-cholesterol-and-triglycerides-in-mixed-hyperlipidemia-patients 2025-05-10T00:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/cns-pharmaceuticals-reports-berubicin-trial-results-in-glioblastoma-patients 2025-05-10T00:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cns-pharmaceuticals-reports-berubicin-trial-results-in-glioblastoma-patients 2025-05-10T00:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-to-present-first-phase-1-data-for-gene-therapy-in-rare-heart-condition-at-asgct 2025-05-10T00:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-to-present-first-phase-1-data-for-gene-therapy-in-rare-heart-condition-at-asgct 2025-05-10T00:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/applied-therapeutics-to-present-extended-inspire-trial-data-for-govorestat-in-sord-deficiency-at-pns-annual-meeting 2025-05-10T00:13:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-therapeutics-to-present-extended-inspire-trial-data-for-govorestat-in-sord-deficiency-at-pns-annual-meeting 2025-05-10T00:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/leucine-rich-bio-expands-global-footprint-launches-bugspeaks-gut-microbiome-test-in-qatar 2025-05-10T00:12:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leucine-rich-bio-expands-global-footprint-launches-bugspeaks-gut-microbiome-test-in-qatar 2025-05-10T00:12:55+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-q1-updates-new-drug-launches-and-fda-extension-for-cytokinetics-aficamten 2025-05-10T00:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-q1-updates-new-drug-launches-and-fda-extension-for-cytokinetics-aficamten 2025-05-10T00:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/digital-health-technologies-and-ai-show-promise-for-transforming-lysosomal-storage-disorder-care-in-europe 2025-05-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-health-technologies-and-ai-show-promise-for-transforming-lysosomal-storage-disorder-care-in-europe 2025-05-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-initiates-pdufa-viii-reauthorization-process-with-public-meeting-and-assessment-report 2025-05-09T23:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-initiates-pdufa-viii-reauthorization-process-with-public-meeting-and-assessment-report 2025-05-09T23:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/durvalumab-combination-shows-disease-free-survival-improvement-in-high-risk-non-muscle-invasive-bladder-cancer 2025-05-09T23:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/durvalumab-combination-shows-disease-free-survival-improvement-in-high-risk-non-muscle-invasive-bladder-cancer 2025-05-09T23:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-royalty-rates-from-2010-2025 2025-05-09T22:42:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-reveals-trends-in-pharmaceutical-and-biotechnology-royalty-rates-from-2010-2025 2025-05-09T22:42:02+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-technologies-completes-1-1m-public-offering-following-otc-pink-transition 2025-05-09T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-technologies-completes-1-1m-public-offering-following-otc-pink-transition 2025-05-09T22:12:50+00:00 hourly 0.9 https://trial.medpath.com/news/nigerian-firm-codix-bio-secures-first-who-backed-license-to-manufacture-rapid-diagnostic-tests-in-africa 2025-05-09T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigerian-firm-codix-bio-secures-first-who-backed-license-to-manufacture-rapid-diagnostic-tests-in-africa 2025-05-09T22:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/nkgen-biotech-ceo-invests-2-65-million-of-personal-funds-to-advance-alzheimer-s-cell-therapy-trial 2025-05-09T21:41:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkgen-biotech-ceo-invests-2-65-million-of-personal-funds-to-advance-alzheimer-s-cell-therapy-trial 2025-05-09T21:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-s-prl3-zumab-shows-promise-in-phase-ii-trial-for-treatment-resistant-solid-tumors 2025-05-09T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-s-prl3-zumab-shows-promise-in-phase-ii-trial-for-treatment-resistant-solid-tumors 2025-05-09T21:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/hillhurst-bio-secures-6-3-million-in-grants-to-advance-novel-parkinson-s-disease-treatment 2025-05-09T21:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hillhurst-bio-secures-6-3-million-in-grants-to-advance-novel-parkinson-s-disease-treatment 2025-05-09T21:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/roche-invests-283-million-in-shanghai-biologics-facility-for-eye-disease-treatment 2025-05-09T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-invests-283-million-in-shanghai-biologics-facility-for-eye-disease-treatment 2025-05-09T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/abvc-biopharma-secures-japanese-patent-for-botanical-depression-treatment-through-2040 2025-05-09T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abvc-biopharma-secures-japanese-patent-for-botanical-depression-treatment-through-2040 2025-05-09T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/nuevocor-secures-us-45-million-series-b-funding-to-advance-gene-therapy-for-genetic-cardiomyopathy 2025-05-09T20:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuevocor-secures-us-45-million-series-b-funding-to-advance-gene-therapy-for-genetic-cardiomyopathy 2025-05-09T20:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-opens-300-million-cell-therapy-manufacturing-facility-in-rockville-maryland 2025-05-09T20:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-opens-300-million-cell-therapy-manufacturing-facility-in-rockville-maryland 2025-05-09T20:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/sublocade-shows-promise-as-safe-treatment-option-for-opioid-use-disorder-during-pregnancy 2025-05-09T20:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sublocade-shows-promise-as-safe-treatment-option-for-opioid-use-disorder-during-pregnancy 2025-05-09T20:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/novel-immunotherapies-and-targeted-agents-show-promise-in-myelodysplastic-syndromes-treatment-landscape 2025-05-09T20:37:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-immunotherapies-and-targeted-agents-show-promise-in-myelodysplastic-syndromes-treatment-landscape 2025-05-09T20:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/kelonia-therapeutics-to-present-novel-in-vivo-gene-delivery-system-data-at-asgct-2025 2025-05-09T20:18:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelonia-therapeutics-to-present-novel-in-vivo-gene-delivery-system-data-at-asgct-2025 2025-05-09T20:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/haic-with-folfox-plus-camrelizumab-and-sorafenib-shows-limited-efficacy-in-advanced-hcc 2025-05-09T20:17:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haic-with-folfox-plus-camrelizumab-and-sorafenib-shows-limited-efficacy-in-advanced-hcc 2025-05-09T20:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/protalix-advances-prx-115-gout-treatment-to-phase-ii-following-promising-early-results-and-strong-q1-revenue 2025-05-09T20:17:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protalix-advances-prx-115-gout-treatment-to-phase-ii-following-promising-early-results-and-strong-q1-revenue 2025-05-09T20:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/eu-proposes-critical-medicines-act-to-address-supply-chain-vulnerabilities-and-reduce-import-dependency 2025-05-09T20:15:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-proposes-critical-medicines-act-to-address-supply-chain-vulnerabilities-and-reduce-import-dependency 2025-05-09T20:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/weightwatchers-files-for-bankruptcy-as-glp-1-weight-loss-drugs-reshape-industry 2025-05-09T19:44:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weightwatchers-files-for-bankruptcy-as-glp-1-weight-loss-drugs-reshape-industry 2025-05-09T19:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/nkure-and-crispr-therapeutics-partner-to-develop-off-the-shelf-car-t-therapy-for-cancer-in-india 2025-05-09T19:38:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nkure-and-crispr-therapeutics-partner-to-develop-off-the-shelf-car-t-therapy-for-cancer-in-india 2025-05-09T19:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/shifting-landscape-5eu-markets-show-significant-changes-in-hta-decisions-and-drug-pricing-in-q1-2025 2025-05-09T19:38:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shifting-landscape-5eu-markets-show-significant-changes-in-hta-decisions-and-drug-pricing-in-q1-2025 2025-05-09T19:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/systimmune-to-present-promising-data-on-iza-bren-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-05-09T19:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systimmune-to-present-promising-data-on-iza-bren-for-her2-negative-breast-cancer-at-esmo-breast-2025 2025-05-09T19:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-halves-workforce-and-refocuses-cancer-drug-development-amid-market-challenges 2025-05-09T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-halves-workforce-and-refocuses-cancer-drug-development-amid-market-challenges 2025-05-09T19:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/minaris-advanced-therapies-launches-as-global-cell-therapy-cdmo-powerhouse 2025-05-09T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minaris-advanced-therapies-launches-as-global-cell-therapy-cdmo-powerhouse 2025-05-09T19:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-reshuffles-executive-leadership-to-accelerate-global-growth-strategy 2025-05-09T18:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-reshuffles-executive-leadership-to-accelerate-global-growth-strategy 2025-05-09T18:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-s-formosa-pharmaceuticals-signs-exclusive-licensing-deal-with-almac-discovery-for-adc-development 2025-05-09T17:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-s-formosa-pharmaceuticals-signs-exclusive-licensing-deal-with-almac-discovery-for-adc-development 2025-05-09T17:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-spotlights-three-late-stage-readouts-as-potential-inflection-point-amid-vyvanse-generic-competition 2025-05-09T17:10:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-spotlights-three-late-stage-readouts-as-potential-inflection-point-amid-vyvanse-generic-competition 2025-05-09T17:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/target-rwe-showcases-groundbreaking-liver-disease-research-at-easl-congress-2025 2025-05-09T16:43:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/target-rwe-showcases-groundbreaking-liver-disease-research-at-easl-congress-2025 2025-05-09T16:43:25+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-250-million-to-expand-purdue-university-research-alliance-through-2032 2025-05-09T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-commits-250-million-to-expand-purdue-university-research-alliance-through-2032 2025-05-09T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/crinecerfont-shows-promise-in-pediatric-congenital-adrenal-hyperplasia-across-all-patient-subgroups 2025-05-09T16:42:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crinecerfont-shows-promise-in-pediatric-congenital-adrenal-hyperplasia-across-all-patient-subgroups 2025-05-09T16:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-and-qilu-pharmaceuticals-partner-on-b7-h3-adc-development-in-210-million-deal-for-greater-china 2025-05-09T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minghui-and-qilu-pharmaceuticals-partner-on-b7-h3-adc-development-in-210-million-deal-for-greater-china 2025-05-09T16:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/galimedix-advances-oral-gal-101-therapy-for-alzheimer-s-and-eye-diseases-in-phase-1-trial 2025-05-09T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galimedix-advances-oral-gal-101-therapy-for-alzheimer-s-and-eye-diseases-in-phase-1-trial 2025-05-09T16:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/perfuse-therapeutics-per-001-shows-promise-as-first-disease-modifying-treatment-for-glaucoma-in-phase-1-2a-trial 2025-05-09T16:41:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfuse-therapeutics-per-001-shows-promise-as-first-disease-modifying-treatment-for-glaucoma-in-phase-1-2a-trial 2025-05-09T16:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-validates-decisiondx-um-test-with-prame-biomarker-for-improved-uveal-melanoma-risk-stratification 2025-05-09T16:41:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-validates-decisiondx-um-test-with-prame-biomarker-for-improved-uveal-melanoma-risk-stratification 2025-05-09T16:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/genefab-and-regcell-partner-to-advance-novel-treg-cell-therapy-for-autoimmune-diseases-into-us-clinical-trials 2025-05-09T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genefab-and-regcell-partner-to-advance-novel-treg-cell-therapy-for-autoimmune-diseases-into-us-clinical-trials 2025-05-09T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-and-purdue-university-forge-historic-250-million-pharmaceutical-innovation-partnership 2025-05-09T16:40:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-and-purdue-university-forge-historic-250-million-pharmaceutical-innovation-partnership 2025-05-09T16:40:41+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-secures-exclusive-license-for-novel-bispecific-adc-targeting-egfr-ror1-solid-tumors 2025-05-09T16:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-secures-exclusive-license-for-novel-bispecific-adc-targeting-egfr-ror1-solid-tumors 2025-05-09T16:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-secures-123-million-series-e-funding-to-advance-ai-driven-drug-discovery-pipeline 2025-05-09T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-secures-123-million-series-e-funding-to-advance-ai-driven-drug-discovery-pipeline 2025-05-09T16:40:12+00:00 hourly 0.9 https://trial.medpath.com/news/sirius-therapeutics-secures-50-million-in-series-b2-funding-to-advance-sirna-therapies-for-cardiometabolic-diseases 2025-05-09T16:40:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirius-therapeutics-secures-50-million-in-series-b2-funding-to-advance-sirna-therapies-for-cardiometabolic-diseases 2025-05-09T16:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/new-abiraterone-formulation-shows-equivalent-efficacy-at-lower-dose-for-metastatic-prostate-cancer 2025-05-09T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-abiraterone-formulation-shows-equivalent-efficacy-at-lower-dose-for-metastatic-prostate-cancer 2025-05-09T16:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/omrx-oncology-launches-phase-2-trial-of-novel-oral-pd-l1-inhibitor-for-nsclc-targeting-global-access-disparities 2025-05-09T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omrx-oncology-launches-phase-2-trial-of-novel-oral-pd-l1-inhibitor-for-nsclc-targeting-global-access-disparities 2025-05-09T16:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/east-africa-launches-regional-drug-research-hub-in-kenya-and-expands-health-security-network 2025-05-09T16:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/east-africa-launches-regional-drug-research-hub-in-kenya-and-expands-health-security-network 2025-05-09T16:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-scrt-plus-camrelizumab-shows-promising-3-year-survival-in-locally-advanced-rectal-cancer 2025-05-09T16:39:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-scrt-plus-camrelizumab-shows-promising-3-year-survival-in-locally-advanced-rectal-cancer 2025-05-09T16:39:29+00:00 hourly 0.9 https://trial.medpath.com/news/path-ex-secures-5-million-to-advance-novel-sepsis-treatment-device-cyclope 2025-05-09T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/path-ex-secures-5-million-to-advance-novel-sepsis-treatment-device-cyclope 2025-05-09T16:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/quanthealth-launches-first-clinical-trial-foundation-model-on-aws-marketplace 2025-05-09T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanthealth-launches-first-clinical-trial-foundation-model-on-aws-marketplace 2025-05-09T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/think-bioscience-and-crystalsfirst-expand-partnership-to-tackle-undruggable-targets 2025-05-09T16:39:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/think-bioscience-and-crystalsfirst-expand-partnership-to-tackle-undruggable-targets 2025-05-09T16:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-misses-review-deadline-for-gsk-s-nucala-copd-expansion-amid-regulatory-delays 2025-05-09T16:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-misses-review-deadline-for-gsk-s-nucala-copd-expansion-amid-regulatory-delays 2025-05-09T16:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-at-home-cervical-cancer-screening-test-expanding-access-to-preventive-care 2025-05-09T16:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-at-home-cervical-cancer-screening-test-expanding-access-to-preventive-care 2025-05-09T16:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/indonesia-launches-phase-3-trial-of-m72-tuberculosis-vaccine-amid-safety-assurances 2025-05-09T15:57:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indonesia-launches-phase-3-trial-of-m72-tuberculosis-vaccine-amid-safety-assurances 2025-05-09T15:57:21+00:00 hourly 0.9 https://trial.medpath.com/news/optigo-biotherapeutics-develops-long-acting-anti-vegf-therapy-with-six-month-dosing-potential 2025-05-09T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optigo-biotherapeutics-develops-long-acting-anti-vegf-therapy-with-six-month-dosing-potential 2025-05-09T15:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-s-oral-glp-1-orforglipron-shows-promising-results-in-phase-3-trial 2025-05-09T14:38:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-s-oral-glp-1-orforglipron-shows-promising-results-in-phase-3-trial 2025-05-09T14:38:34+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-s-temtokibart-shows-promising-results-in-phase-2b-trial-for-moderate-to-severe-atopic-dermatitis 2025-05-09T13:38:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-s-temtokibart-shows-promising-results-in-phase-2b-trial-for-moderate-to-severe-atopic-dermatitis 2025-05-09T13:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/ema-suspends-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-09T13:38:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-suspends-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-09T13:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/bombay-hc-challenges-cdsco-s-rejection-of-indigenous-cancer-immunotherapy-trial 2025-05-09T12:36:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bombay-hc-challenges-cdsco-s-rejection-of-indigenous-cancer-immunotherapy-trial 2025-05-09T12:36:19+00:00 hourly 0.9 https://trial.medpath.com/news/pharmac-to-fund-advanced-melanoma-treatments-in-new-zealand-starting-june-2025 2025-05-09T12:36:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmac-to-fund-advanced-melanoma-treatments-in-new-zealand-starting-june-2025 2025-05-09T12:36:17+00:00 hourly 0.9 https://trial.medpath.com/news/novagold-completes-179-million-public-offering-to-advance-donlin-gold-project-development 2025-05-09T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novagold-completes-179-million-public-offering-to-advance-donlin-gold-project-development 2025-05-09T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/biowell-partners-with-texas-biotechnology-to-create-largest-public-industrial-biomanufacturing-facility-in-the-us 2025-05-09T10:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biowell-partners-with-texas-biotechnology-to-create-largest-public-industrial-biomanufacturing-facility-in-the-us 2025-05-09T10:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/neurofibromatoses-pipeline-shows-strong-activity-with-12-therapies-in-development-across-multiple-clinical-stages 2025-05-09T10:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurofibromatoses-pipeline-shows-strong-activity-with-12-therapies-in-development-across-multiple-clinical-stages 2025-05-09T10:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/rectify-pharma-s-novel-dual-targeted-pfm-shows-promise-for-hepatobiliary-diseases-at-easl-2025 2025-05-09T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rectify-pharma-s-novel-dual-targeted-pfm-shows-promise-for-hepatobiliary-diseases-at-easl-2025 2025-05-09T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-scientists-develop-breakthrough-mrna-vaccine-strategy-for-decades-long-immunity 2025-05-09T09:40:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-scientists-develop-breakthrough-mrna-vaccine-strategy-for-decades-long-immunity 2025-05-09T09:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/ascidian-therapeutics-advances-rna-exon-editing-platform-with-key-leadership-appointments-and-clinical-progress 2025-05-09T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascidian-therapeutics-advances-rna-exon-editing-platform-with-key-leadership-appointments-and-clinical-progress 2025-05-09T09:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/lenz-therapeutics-and-lotus-pharmaceutical-forge-125-million-deal-for-presbyopia-treatment-in-southeast-asia 2025-05-09T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenz-therapeutics-and-lotus-pharmaceutical-forge-125-million-deal-for-presbyopia-treatment-in-southeast-asia 2025-05-09T09:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/diabetes-drug-pioglitazone-shows-promising-anti-tumor-effects-in-prostate-cancer 2025-05-09T08:38:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diabetes-drug-pioglitazone-shows-promising-anti-tumor-effects-in-prostate-cancer 2025-05-09T08:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/aribio-and-fujirebio-complete-major-biomarker-sample-collection-for-alzheimer-s-research-in-phase-3-polaris-ad-trial 2025-05-09T08:37:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aribio-and-fujirebio-complete-major-biomarker-sample-collection-for-alzheimer-s-research-in-phase-3-polaris-ad-trial 2025-05-09T08:37:55+00:00 hourly 0.9 https://trial.medpath.com/news/queen-mary-researchers-develop-novel-model-for-recurrent-glioblastoma-treatment-using-repurposed-antiparasitic-drug 2025-05-09T08:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/queen-mary-researchers-develop-novel-model-for-recurrent-glioblastoma-treatment-using-repurposed-antiparasitic-drug 2025-05-09T08:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-s-rystiggo-r-rozanolixizumab-approved-in-japan-for-at-home-self-administration-in-gmg-patients 2025-05-09T08:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-s-rystiggo-r-rozanolixizumab-approved-in-japan-for-at-home-self-administration-in-gmg-patients 2025-05-09T08:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/rocket-pharmaceuticals-advances-gene-therapy-pipeline-with-key-updates-on-danon-disease-and-pkp2-acm-programs 2025-05-09T08:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-advances-gene-therapy-pipeline-with-key-updates-on-danon-disease-and-pkp2-acm-programs 2025-05-09T08:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-pathology-transforming-cancer-diagnostics-and-precision-oncology 2025-05-09T08:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-pathology-transforming-cancer-diagnostics-and-precision-oncology 2025-05-09T08:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-to-acquire-japan-tobacco-s-pharmaceutical-subsidiaries-for-1-1-billion 2025-05-09T08:01:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-to-acquire-japan-tobacco-s-pharmaceutical-subsidiaries-for-1-1-billion 2025-05-09T08:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/nice-opens-consultations-for-two-targeted-therapies-in-advanced-non-small-cell-lung-cancer 2025-05-09T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-opens-consultations-for-two-targeted-therapies-in-advanced-non-small-cell-lung-cancer 2025-05-09T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/vivo-capital-secures-740-million-for-third-cycle-of-healthcare-investment-fund 2025-05-09T07:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivo-capital-secures-740-million-for-third-cycle-of-healthcare-investment-fund 2025-05-09T07:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/elutia-announces-strong-first-quarter-2025-financial-results-driven-by-84-sequential-growth-in-eluprotm-sales 2025-05-09T07:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elutia-announces-strong-first-quarter-2025-financial-results-driven-by-84-sequential-growth-in-eluprotm-sales 2025-05-09T07:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-linerixibat-shows-significant-improvement-in-cholestatic-pruritus-for-primary-biliary-cholangitis-patients 2025-05-09T06:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-linerixibat-shows-significant-improvement-in-cholestatic-pruritus-for-primary-biliary-cholangitis-patients 2025-05-09T06:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/novel-blood-test-could-guide-precision-treatment-for-resistant-lupus-with-rituximab-belimumab-combination 2025-05-09T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-blood-test-could-guide-precision-treatment-for-resistant-lupus-with-rituximab-belimumab-combination 2025-05-09T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/upmc-enterprises-leads-18-25-million-series-b1-investment-in-carta-healthcare-for-ai-powered-clinical-data-management 2025-05-09T06:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upmc-enterprises-leads-18-25-million-series-b1-investment-in-carta-healthcare-for-ai-powered-clinical-data-management 2025-05-09T06:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/vor-bio-halts-clinical-operations-and-explores-strategic-alternatives-amid-financial-challenges 2025-05-09T06:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vor-bio-halts-clinical-operations-and-explores-strategic-alternatives-amid-financial-challenges 2025-05-09T06:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/ludwig-enterprises-unveils-revealia-breast-a-revolutionary-cheek-swab-test-for-early-breast-cancer-detection 2025-05-09T06:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ludwig-enterprises-unveils-revealia-breast-a-revolutionary-cheek-swab-test-for-early-breast-cancer-detection 2025-05-09T06:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/ionq-expands-quantum-computing-portfolio-through-strategic-acquisitions-of-lightsynq-and-id-quantique 2025-05-09T05:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionq-expands-quantum-computing-portfolio-through-strategic-acquisitions-of-lightsynq-and-id-quantique 2025-05-09T05:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/cb-scientific-rebrands-as-cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-global-rollout 2025-05-09T05:38:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cb-scientific-rebrands-as-cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-global-rollout 2025-05-09T05:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/merck-animal-health-commits-895-million-to-expand-kansas-manufacturing-and-r-d-facilities 2025-05-09T05:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-animal-health-commits-895-million-to-expand-kansas-manufacturing-and-r-d-facilities 2025-05-09T05:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/paq-therapeutics-secures-39m-series-b-funding-and-launches-phase-1-trial-for-novel-kras-g12d-degrader 2025-05-09T05:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paq-therapeutics-secures-39m-series-b-funding-and-launches-phase-1-trial-for-novel-kras-g12d-degrader 2025-05-09T05:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/disc-medicine-advances-bitopertin-nda-for-erythropoietic-protoporphyria-as-pipeline-progress-continues 2025-05-09T04:41:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/disc-medicine-advances-bitopertin-nda-for-erythropoietic-protoporphyria-as-pipeline-progress-continues 2025-05-09T04:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/five-leading-companies-form-lnp-alliance-to-accelerate-nanoparticle-based-drug-development 2025-05-09T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-leading-companies-form-lnp-alliance-to-accelerate-nanoparticle-based-drug-development 2025-05-09T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-urgent-warning-against-gas-station-heroin-tianeptine-citing-severe-health-risks 2025-05-09T04:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-urgent-warning-against-gas-station-heroin-tianeptine-citing-severe-health-risks 2025-05-09T04:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/redesign-health-and-cedars-sinai-form-strategic-partnership-to-launch-multiple-healthcare-companies 2025-05-09T04:39:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redesign-health-and-cedars-sinai-form-strategic-partnership-to-launch-multiple-healthcare-companies 2025-05-09T04:39:23+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-and-cilcare-partner-in-eur400m-deal-to-develop-novel-hearing-loss-treatments 2025-05-09T04:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-and-cilcare-partner-in-eur400m-deal-to-develop-novel-hearing-loss-treatments 2025-05-09T04:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-pledges-30b-in-u-s-argues-against-trumps-most-favored-nations-proposal 2025-05-09T04:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-pledges-30b-in-u-s-argues-against-trumps-most-favored-nations-proposal 2025-05-09T04:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/tfs-healthscience-and-oncomatryx-advance-novel-fap-adc-to-phase-ib-trial-for-pancreatic-cancer 2025-05-09T04:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tfs-healthscience-and-oncomatryx-advance-novel-fap-adc-to-phase-ib-trial-for-pancreatic-cancer 2025-05-09T04:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/appeals-court-rejects-astrazeneca-s-challenge-to-medicare-drug-price-negotiation-program 2025-05-09T04:09:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appeals-court-rejects-astrazeneca-s-challenge-to-medicare-drug-price-negotiation-program 2025-05-09T04:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/osaka-university-develops-promising-immune-cell-therapy-for-acute-myeloid-leukemia 2025-05-09T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osaka-university-develops-promising-immune-cell-therapy-for-acute-myeloid-leukemia 2025-05-09T04:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/new-challenges-emerge-in-transitioning-cidp-patients-from-ivig-to-efgartigimod 2025-05-09T04:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-challenges-emerge-in-transitioning-cidp-patients-from-ivig-to-efgartigimod 2025-05-09T04:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/sigachi-industries-secures-european-certification-for-metformin-hydrochloride-api 2025-05-09T04:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sigachi-industries-secures-european-certification-for-metformin-hydrochloride-api 2025-05-09T04:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/nppa-sets-retail-prices-for-84-drugs-including-empagliflozin-combinations-following-patent-expiry 2025-05-09T04:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nppa-sets-retail-prices-for-84-drugs-including-empagliflozin-combinations-following-patent-expiry 2025-05-09T04:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/ingenus-pharmaceuticals-advances-cancer-drug-patent-suit-against-nexus-court-dismisses-co-plaintiff 2025-05-09T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenus-pharmaceuticals-advances-cancer-drug-patent-suit-against-nexus-court-dismisses-co-plaintiff 2025-05-09T04:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/karma-biosciences-files-patents-for-rapid-acting-nasal-pde-5-inhibitors-with-5-minute-onset 2025-05-09T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/karma-biosciences-files-patents-for-rapid-acting-nasal-pde-5-inhibitors-with-5-minute-onset 2025-05-09T04:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-and-sona-nanotech-partner-to-develop-novel-cancer-immunotherapy-combining-dpx-platform-with-gold-nanorod-technology 2025-05-09T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-and-sona-nanotech-partner-to-develop-novel-cancer-immunotherapy-combining-dpx-platform-with-gold-nanorod-technology 2025-05-09T04:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/genezen-and-optieum-partner-to-manufacture-lentiviral-vectors-for-novel-glioblastoma-car-t-therapy 2025-05-09T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genezen-and-optieum-partner-to-manufacture-lentiviral-vectors-for-novel-glioblastoma-car-t-therapy 2025-05-09T04:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/dawn-health-secures-eur11-5-million-to-expand-pharma-focused-digital-health-platform 2025-05-09T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dawn-health-secures-eur11-5-million-to-expand-pharma-focused-digital-health-platform 2025-05-09T04:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/leqvio-emerges-as-leading-pcsk9-inhibitor-in-cholesterol-management-across-major-markets 2025-05-09T04:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leqvio-emerges-as-leading-pcsk9-inhibitor-in-cholesterol-management-across-major-markets 2025-05-09T04:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-reports-15-revenue-growth-in-q4fy25-launches-fifth-biosimilar-in-u-s-market 2025-05-09T04:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-reports-15-revenue-growth-in-q4fy25-launches-fifth-biosimilar-in-u-s-market 2025-05-09T04:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/nuvalent-advances-toward-first-nda-submission-with-pivotal-data-expected-for-ros1-and-alk-inhibitors-in-2025 2025-05-09T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvalent-advances-toward-first-nda-submission-with-pivotal-data-expected-for-ros1-and-alk-inhibitors-in-2025 2025-05-09T04:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-schedules-investor-conference-presentations-for-may-and-june-2025 2025-05-09T04:04:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-schedules-investor-conference-presentations-for-may-and-june-2025 2025-05-09T04:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/peptone-and-evotec-form-strategic-alliance-to-develop-novel-therapeutics-targeting-intrinsically-disordered-proteins 2025-05-09T04:04:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptone-and-evotec-form-strategic-alliance-to-develop-novel-therapeutics-targeting-intrinsically-disordered-proteins 2025-05-09T04:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-reports-63-revenue-growth-in-q1-2025-prepares-to-share-clinical-data-for-sgr-1505 2025-05-09T04:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-reports-63-revenue-growth-in-q1-2025-prepares-to-share-clinical-data-for-sgr-1505 2025-05-09T04:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/lexaria-bioscience-advances-dehydratech-platform-to-enhance-glp-1-drug-effectiveness 2025-05-09T04:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexaria-bioscience-advances-dehydratech-platform-to-enhance-glp-1-drug-effectiveness 2025-05-09T04:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/10-year-data-confirms-1-week-radiotherapy-as-effective-as-3-week-course-for-early-stage-breast-cancer 2025-05-09T01:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10-year-data-confirms-1-week-radiotherapy-as-effective-as-3-week-course-for-early-stage-breast-cancer 2025-05-09T01:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/uic-researchers-develop-groundbreaking-antibiotic-against-superbugs-as-illinois-faces-rising-antimicrobial-resistance 2025-05-09T01:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uic-researchers-develop-groundbreaking-antibiotic-against-superbugs-as-illinois-faces-rising-antimicrobial-resistance 2025-05-09T01:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/utr-therapeutics-submits-ind-for-novel-mrna-destabilizing-drug-targeting-c-myc-in-multiple-cancers 2025-05-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/utr-therapeutics-submits-ind-for-novel-mrna-destabilizing-drug-targeting-c-myc-in-multiple-cancers 2025-05-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-advances-fast-acting-meloxicam-toward-fda-submission-following-successful-phase-iii-trials 2025-05-09T01:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-advances-fast-acting-meloxicam-toward-fda-submission-following-successful-phase-iii-trials 2025-05-09T01:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-myh9-gene-variant-identified-in-chinese-child-with-rare-hereditary-thrombocytopenia 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-myh9-gene-variant-identified-in-chinese-child-with-rare-hereditary-thrombocytopenia 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-contact-force-sensing-pulsed-field-ablation-catheter-shows-promise-in-paroxysmal-af-treatment 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-contact-force-sensing-pulsed-field-ablation-catheter-shows-promise-in-paroxysmal-af-treatment 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hilo-secures-42-million-series-b-funding-to-revolutionize-blood-pressure-monitoring 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hilo-secures-42-million-series-b-funding-to-revolutionize-blood-pressure-monitoring 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurofibromatosis-type-1-with-plexiform-neurofibromas-diagnosis-epidemiology-and-clinical-manifestations 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurofibromatosis-type-1-with-plexiform-neurofibromas-diagnosis-epidemiology-and-clinical-manifestations 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-commissioner-signals-shift-in-covid-19-booster-strategy-requiring-stronger-clinical-evidence 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-commissioner-signals-shift-in-covid-19-booster-strategy-requiring-stronger-clinical-evidence 2025-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-leadership-shuffle-key-executive-moves-in-early-2025-reshape-industry-landscape 2025-05-08T23:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-leadership-shuffle-key-executive-moves-in-early-2025-reshape-industry-landscape 2025-05-08T23:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/hyperuricemia-pipeline-shows-promise-with-15-emerging-therapies-in-development 2025-05-08T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperuricemia-pipeline-shows-promise-with-15-emerging-therapies-in-development 2025-05-08T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/hepatitis-d-pipeline-shows-strong-progress-with-multiple-fda-breakthrough-designations-and-promising-phase-3-results 2025-05-08T22:40:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatitis-d-pipeline-shows-strong-progress-with-multiple-fda-breakthrough-designations-and-promising-phase-3-results 2025-05-08T22:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/lupus-nephritis-market-expected-to-grow-as-novel-therapies-enter-clinical-trials 2025-05-08T22:40:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupus-nephritis-market-expected-to-grow-as-novel-therapies-enter-clinical-trials 2025-05-08T22:40:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-deploy-ai-assistant-across-all-centers-by-june-30-to-accelerate-scientific-reviews 2025-05-08T22:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-deploy-ai-assistant-across-all-centers-by-june-30-to-accelerate-scientific-reviews 2025-05-08T22:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/adavosertib-shows-promise-in-uterine-serous-carcinoma-despite-tolerability-challenges 2025-05-08T22:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adavosertib-shows-promise-in-uterine-serous-carcinoma-despite-tolerability-challenges 2025-05-08T22:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/fast-forward-trial-one-week-breast-cancer-radiotherapy-proven-equally-effective-as-three-week-standard 2025-05-08T21:15:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fast-forward-trial-one-week-breast-cancer-radiotherapy-proven-equally-effective-as-three-week-standard 2025-05-08T21:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/apimeds-pharmaceuticals-raises-13-5-million-in-ipo-for-bee-venom-based-therapy-development 2025-05-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apimeds-pharmaceuticals-raises-13-5-million-in-ipo-for-bee-venom-based-therapy-development 2025-05-08T21:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/signatera-ctdna-test-predicts-recurrence-risk-in-high-risk-breast-cancer-patients-i-spy-2-trial-data-shows 2025-05-08T19:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/signatera-ctdna-test-predicts-recurrence-risk-in-high-risk-breast-cancer-patients-i-spy-2-trial-data-shows 2025-05-08T19:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/panitumumab-plus-folfox-significantly-improves-survival-in-ras-braf-wild-type-locally-advanced-colon-cancer 2025-05-08T19:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panitumumab-plus-folfox-significantly-improves-survival-in-ras-braf-wild-type-locally-advanced-colon-cancer 2025-05-08T19:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-miplyffa-for-niemann-pick-type-c-disease-offering-new-hope-for-rare-genetic-disorder 2025-05-08T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-miplyffa-for-niemann-pick-type-c-disease-offering-new-hope-for-rare-genetic-disorder 2025-05-08T19:35:46+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-drugs-show-promising-potential-to-reduce-alzheimer-s-risk-by-up-to-13-annually 2025-05-08T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-drugs-show-promising-potential-to-reduce-alzheimer-s-risk-by-up-to-13-annually 2025-05-08T19:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/oryzon-genomics-secures-eur13-26-million-eu-grant-for-rare-disease-research 2025-05-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oryzon-genomics-secures-eur13-26-million-eu-grant-for-rare-disease-research 2025-05-08T17:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-wireless-device-enables-remote-activation-of-light-sensitive-drugs-for-pain-management 2025-05-08T17:37:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-wireless-device-enables-remote-activation-of-light-sensitive-drugs-for-pain-management 2025-05-08T17:37:46+00:00 hourly 0.9 https://trial.medpath.com/news/junshi-biosciences-receives-ind-approval-for-novel-bispecific-adc-targeting-egfr-and-her3 2025-05-08T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junshi-biosciences-receives-ind-approval-for-novel-bispecific-adc-targeting-egfr-and-her3 2025-05-08T17:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-study-advanced-mri-and-focal-therapy-revolutionize-prostate-cancer-surveillance 2025-05-08T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-study-advanced-mri-and-focal-therapy-revolutionize-prostate-cancer-surveillance 2025-05-08T17:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-secures-65m-to-develop-drugs-targeting-the-dark-genome 2025-05-08T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haya-therapeutics-secures-65m-to-develop-drugs-targeting-the-dark-genome 2025-05-08T17:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/vintabio-showcases-high-efficiency-aav-vector-production-platform-at-asgct-2025 2025-05-08T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vintabio-showcases-high-efficiency-aav-vector-production-platform-at-asgct-2025 2025-05-08T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/eu-regulator-confirms-suicidal-thoughts-as-rare-side-effect-of-hair-loss-drug-finasteride 2025-05-08T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-regulator-confirms-suicidal-thoughts-as-rare-side-effect-of-hair-loss-drug-finasteride 2025-05-08T17:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/alphagen-intelligence-corp-announces-195000-private-placement-for-working-capital 2025-05-08T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alphagen-intelligence-corp-announces-195000-private-placement-for-working-capital 2025-05-08T16:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioarctic-expands-exidavnemab-phase-2a-trial-to-include-multiple-system-atrophy-patients 2025-05-08T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioarctic-expands-exidavnemab-phase-2a-trial-to-include-multiple-system-atrophy-patients 2025-05-08T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-q1-2025-results-pipeline-progress-despite-financial-challenges 2025-05-08T16:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-q1-2025-results-pipeline-progress-despite-financial-challenges 2025-05-08T16:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-secures-65-million-series-a-to-advance-rna-guided-medicines-targeting-the-dark-genome 2025-05-08T16:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haya-therapeutics-secures-65-million-series-a-to-advance-rna-guided-medicines-targeting-the-dark-genome 2025-05-08T16:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/crenessity-shows-consistent-efficacy-across-pediatric-cah-subgroups-while-reducing-glucocorticoid-doses 2025-05-08T16:37:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crenessity-shows-consistent-efficacy-across-pediatric-cah-subgroups-while-reducing-glucocorticoid-doses 2025-05-08T16:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/yamo-pharmaceuticals-reports-breakthrough-phase-2-results-for-novel-autism-treatment-l1-79 2025-05-08T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yamo-pharmaceuticals-reports-breakthrough-phase-2-results-for-novel-autism-treatment-l1-79 2025-05-08T16:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/cytophage-secures-canadian-regulatory-approval-for-novel-phage-therapy-targeting-prosthetic-joint-infections 2025-05-08T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytophage-secures-canadian-regulatory-approval-for-novel-phage-therapy-targeting-prosthetic-joint-infections 2025-05-08T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-names-iker-huerga-as-ceo-to-accelerate-ai-driven-oncology-drug-development 2025-05-08T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-names-iker-huerga-as-ceo-to-accelerate-ai-driven-oncology-drug-development 2025-05-08T16:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/vivopower-advances-in-180-million-takeover-deal-with-energi-holdings-as-phase-i-due-diligence-completes 2025-05-08T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivopower-advances-in-180-million-takeover-deal-with-energi-holdings-as-phase-i-due-diligence-completes 2025-05-08T16:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/ss-innovations-to-seek-fda-approval-for-ssi-mantra-3-surgical-robotic-system 2025-05-08T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ss-innovations-to-seek-fda-approval-for-ssi-mantra-3-surgical-robotic-system 2025-05-08T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-broad-spectrum-antiviral-nv-387-advances-to-phase-ii-trials-for-mpox-treatment 2025-05-08T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-broad-spectrum-antiviral-nv-387-advances-to-phase-ii-trials-for-mpox-treatment 2025-05-08T16:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-advances-gene-editing-pipeline-with-key-programs-for-cgd-wilson-s-disease-and-aatd 2025-05-08T14:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-advances-gene-editing-pipeline-with-key-programs-for-cgd-wilson-s-disease-and-aatd 2025-05-08T14:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/vectory-therapeutics-unveils-promising-preclinical-data-for-novel-als-treatment-targeting-oxidized-phospholipids 2025-05-08T14:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vectory-therapeutics-unveils-promising-preclinical-data-for-novel-als-treatment-targeting-oxidized-phospholipids 2025-05-08T14:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/eminent-spine-receives-fda-510-k-clearance-for-world-s-first-3d-printed-titanium-pedicle-screw-system 2025-05-08T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eminent-spine-receives-fda-510-k-clearance-for-world-s-first-3d-printed-titanium-pedicle-screw-system 2025-05-08T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-positive-phase-3-results-for-novel-fast-acting-meloxicam-in-acute-pain-treatment 2025-05-08T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-positive-phase-3-results-for-novel-fast-acting-meloxicam-in-acute-pain-treatment 2025-05-08T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-reports-positive-phase-3-results-for-xulane-lo-low-dose-contraceptive-patch 2025-05-08T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-reports-positive-phase-3-results-for-xulane-lo-low-dose-contraceptive-patch 2025-05-08T13:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/johns-hopkins-study-links-hypoglycemia-to-diabetic-retinopathy-progression-experimental-drug-shows-promise 2025-05-08T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johns-hopkins-study-links-hypoglycemia-to-diabetic-retinopathy-progression-experimental-drug-shows-promise 2025-05-08T13:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-advances-apvo711-novel-bispecific-antibody-combining-pd-l1-checkpoint-inhibition-with-cd40-immune-activation 2025-05-08T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptevo-advances-apvo711-novel-bispecific-antibody-combining-pd-l1-checkpoint-inhibition-with-cd40-immune-activation 2025-05-08T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/nalu-reports-94-response-rate-in-largest-real-world-study-of-peripheral-nerve-stimulation-device 2025-05-08T12:19:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nalu-reports-94-response-rate-in-largest-real-world-study-of-peripheral-nerve-stimulation-device 2025-05-08T12:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/novel-antibody-plt012-targets-fat-metabolism-to-overcome-immunotherapy-resistance-in-cancer 2025-05-08T10:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-antibody-plt012-targets-fat-metabolism-to-overcome-immunotherapy-resistance-in-cancer 2025-05-08T10:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/newlimit-secures-130m-series-b-to-advance-epigenetic-reprogramming-for-age-reversal 2025-05-08T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newlimit-secures-130m-series-b-to-advance-epigenetic-reprogramming-for-age-reversal 2025-05-08T08:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-presents-phase-ii-data-for-amlenetug-in-multiple-system-atrophy-at-international-congress 2025-05-08T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-presents-phase-ii-data-for-amlenetug-in-multiple-system-atrophy-at-international-congress 2025-05-08T07:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-advances-canalevia-ca1-field-study-for-canine-cancer-treatment-as-company-pursues-full-fda-approval 2025-05-08T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-advances-canalevia-ca1-field-study-for-canine-cancer-treatment-as-company-pursues-full-fda-approval 2025-05-08T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/major-depressive-disorder-pipeline-advances-with-75-companies-developing-novel-therapies 2025-05-08T04:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-depressive-disorder-pipeline-advances-with-75-companies-developing-novel-therapies 2025-05-08T04:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-odac-to-review-four-cancer-drugs-in-may-meeting 2025-05-08T04:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-odac-to-review-four-cancer-drugs-in-may-meeting 2025-05-08T04:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/algorae-pharmaceuticals-partners-with-peter-maccallum-cancer-centre-to-validate-ai-predicted-drug-combinations 2025-05-08T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algorae-pharmaceuticals-partners-with-peter-maccallum-cancer-centre-to-validate-ai-predicted-drug-combinations 2025-05-08T04:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/rett-syndrome-pipeline-analysis-reveals-20-companies-developing-novel-therapeutics-with-gene-therapy-leading-innovation 2025-05-08T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rett-syndrome-pipeline-analysis-reveals-20-companies-developing-novel-therapeutics-with-gene-therapy-leading-innovation 2025-05-08T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-report-reveals-promising-pipeline-for-autism-therapeutics-in-2025 2025-05-08T04:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-report-reveals-promising-pipeline-for-autism-therapeutics-in-2025 2025-05-08T04:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioaffinity-technologies-secures-3-25-million-in-funding-to-advance-early-cancer-detection-technology 2025-05-08T02:34:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaffinity-technologies-secures-3-25-million-in-funding-to-advance-early-cancer-detection-technology 2025-05-08T02:34:27+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-rising-influence-in-global-drug-development-bridging-studies-transform-us-clinical-research 2025-05-08T02:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-rising-influence-in-global-drug-development-bridging-studies-transform-us-clinical-research 2025-05-08T02:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-casgevy-shows-commercial-progress-as-gene-therapy-pipeline-advances 2025-05-08T01:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-casgevy-shows-commercial-progress-as-gene-therapy-pipeline-advances 2025-05-08T01:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-jr-446-for-rare-neurological-disorder-mps-iiib 2025-05-08T01:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-jr-446-for-rare-neurological-disorder-mps-iiib 2025-05-08T01:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-cdsco-releases-draft-guidelines-for-biosimilars-approval-with-focus-on-advanced-analytical-methods 2025-05-08T01:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-cdsco-releases-draft-guidelines-for-biosimilars-approval-with-focus-on-advanced-analytical-methods 2025-05-08T01:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-to-acquire-japan-tobacco-s-pharma-units-for-1-1-billion 2025-05-08T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-to-acquire-japan-tobacco-s-pharma-units-for-1-1-billion 2025-05-08T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/texas-proposes-25-million-for-first-fda-approved-ibogaine-clinical-trials-for-ptsd-and-addiction 2025-05-08T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-proposes-25-million-for-first-fda-approved-ibogaine-clinical-trials-for-ptsd-and-addiction 2025-05-08T01:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-abandons-aav-vector-technology-amid-broader-industry-retreat-from-gene-therapy 2025-05-08T01:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-abandons-aav-vector-technology-amid-broader-industry-retreat-from-gene-therapy 2025-05-08T01:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/atrasentan-receives-fda-accelerated-approval-for-iga-nephropathy-after-decades-long-development-journey 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrasentan-receives-fda-accelerated-approval-for-iga-nephropathy-after-decades-long-development-journey 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-ruling-limits-patent-protection-for-machine-learning-applications-highlights-trade-secret-alternative 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-ruling-limits-patent-protection-for-machine-learning-applications-highlights-trade-secret-alternative 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ratio-therapeutics-to-build-65000-sq-ft-radiopharmaceutical-manufacturing-facility-in-salt-lake-city 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ratio-therapeutics-to-build-65000-sq-ft-radiopharmaceutical-manufacturing-facility-in-salt-lake-city 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/emerald-trial-data-reveals-duration-of-prior-cdk4-6-inhibitor-therapy-as-key-predictor-for-elacestrant-success-in-esr1-mutant-breast-cancer 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerald-trial-data-reveals-duration-of-prior-cdk4-6-inhibitor-therapy-as-key-predictor-for-elacestrant-success-in-esr1-mutant-breast-cancer 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brexit-threatens-european-medicine-supply-chain-over-45-million-patient-packs-at-risk-monthly 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brexit-threatens-european-medicine-supply-chain-over-45-million-patient-packs-at-risk-monthly 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-clinical-trials-reveal-advances-in-non-infectious-uveitis-treatment-options 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-clinical-trials-reveal-advances-in-non-infectious-uveitis-treatment-options 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-issues-updated-guidance-on-non-mutagenic-impurity-qualification-to-reduce-animal-testing 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-issues-updated-guidance-on-non-mutagenic-impurity-qualification-to-reduce-animal-testing 2025-05-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hazer-and-kbr-form-strategic-alliance-to-commercialize-low-emission-hydrogen-technology 2025-05-07T22:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hazer-and-kbr-form-strategic-alliance-to-commercialize-low-emission-hydrogen-technology 2025-05-07T22:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-riskscore-study-shows-improved-breast-cancer-screening-personalization 2025-05-07T22:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-riskscore-study-shows-improved-breast-cancer-screening-personalization 2025-05-07T22:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-partners-with-openai-to-accelerate-drug-approval-process-with-ai 2025-05-07T22:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-partners-with-openai-to-accelerate-drug-approval-process-with-ai 2025-05-07T22:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-secures-ce-mark-approval-for-luxlife-full-range-of-vision-intraocular-lens-in-europe 2025-05-07T19:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-secures-ce-mark-approval-for-luxlife-full-range-of-vision-intraocular-lens-in-europe 2025-05-07T19:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/ema-suspends-valneva-s-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-07T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-suspends-valneva-s-ixchiq-chikungunya-vaccine-for-elderly-following-safety-concerns 2025-05-07T19:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/ribbon-bio-strengthens-commercial-leadership-with-jeff-fitzgerald-appointment-as-global-sales-head-amid-mirosynthtm-dna-launch 2025-05-07T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribbon-bio-strengthens-commercial-leadership-with-jeff-fitzgerald-appointment-as-global-sales-head-amid-mirosynthtm-dna-launch 2025-05-07T17:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-raises-6-3-million-to-advance-mek-inhibitor-for-neurofibromatosis-type-1 2025-05-07T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-therapeutics-raises-6-3-million-to-advance-mek-inhibitor-for-neurofibromatosis-type-1 2025-05-07T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dcgi-launches-investigation-into-58-alleged-illegal-clinical-trials-at-vs-hospital-following-supreme-court-intervention 2025-05-07T16:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dcgi-launches-investigation-into-58-alleged-illegal-clinical-trials-at-vs-hospital-following-supreme-court-intervention 2025-05-07T16:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-prospera-heart-test-with-dqs-shows-superior-performance-in-detecting-transplant-rejection 2025-05-07T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-prospera-heart-test-with-dqs-shows-superior-performance-in-detecting-transplant-rejection 2025-05-07T16:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/ribbon-bio-launches-mirosynthtm-dna-platform-to-advance-complex-synthetic-dna-production 2025-05-07T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribbon-bio-launches-mirosynthtm-dna-platform-to-advance-complex-synthetic-dna-production 2025-05-07T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-awards-evotec-2-5m-grant-to-advance-next-generation-tuberculosis-treatments 2025-05-07T16:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gates-foundation-awards-evotec-2-5m-grant-to-advance-next-generation-tuberculosis-treatments 2025-05-07T16:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/tuhura-biosciences-initiates-phase-1b-2a-trial-of-ifx-hu2-0-for-deep-seated-merkel-cell-carcinoma 2025-05-07T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuhura-biosciences-initiates-phase-1b-2a-trial-of-ifx-hu2-0-for-deep-seated-merkel-cell-carcinoma 2025-05-07T16:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/immunewalk-s-iw-601-shows-positive-phase-1-results-in-novel-monocyte-targeting-approach-for-inflammatory-diseases 2025-05-07T13:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunewalk-s-iw-601-shows-positive-phase-1-results-in-novel-monocyte-targeting-approach-for-inflammatory-diseases 2025-05-07T13:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/vigil-neuroscience-advances-dual-trem2-programs-with-promising-results-for-neurodegenerative-diseases 2025-05-07T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vigil-neuroscience-advances-dual-trem2-programs-with-promising-results-for-neurodegenerative-diseases 2025-05-07T13:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/shionogi-receives-regulatory-clearance-for-torii-pharmaceutical-acquisition-tender-offer-proceeds 2025-05-07T13:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shionogi-receives-regulatory-clearance-for-torii-pharmaceutical-acquisition-tender-offer-proceeds 2025-05-07T13:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-s-ak3280-shows-promising-results-in-phase-ii-ipf-trial-with-significant-lung-function-improvement 2025-05-07T13:35:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-s-ak3280-shows-promising-results-in-phase-ii-ipf-trial-with-significant-lung-function-improvement 2025-05-07T13:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/isarna-s-isth0036-shows-promise-in-reducing-retinal-fibrosis-in-phase-2-better-trial 2025-05-07T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isarna-s-isth0036-shows-promise-in-reducing-retinal-fibrosis-in-phase-2-better-trial 2025-05-07T13:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/nefecon-receives-full-nmpa-approval-for-iga-nephropathy-treatment-in-china-removing-proteinuria-restrictions 2025-05-07T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nefecon-receives-full-nmpa-approval-for-iga-nephropathy-treatment-in-china-removing-proteinuria-restrictions 2025-05-07T13:34:14+00:00 hourly 0.9 https://trial.medpath.com/news/corvista-health-validates-non-invasive-pulmonary-hypertension-diagnostic-system-in-major-clinical-study 2025-05-07T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corvista-health-validates-non-invasive-pulmonary-hypertension-diagnostic-system-in-major-clinical-study 2025-05-07T12:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-feder-grant-awarded-to-leo-cancer-care-and-centre-leon-berard-for-upright-radiation-therapy-innovation 2025-05-07T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-feder-grant-awarded-to-leo-cancer-care-and-centre-leon-berard-for-upright-radiation-therapy-innovation 2025-05-07T11:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-discovery-pla2g15-identified-as-novel-target-for-neurometabolic-disorders 2025-05-07T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-discovery-pla2g15-identified-as-novel-target-for-neurometabolic-disorders 2025-05-07T11:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/aboleris-pharma-initiates-first-in-human-trial-of-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis 2025-05-07T10:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aboleris-pharma-initiates-first-in-human-trial-of-novel-anti-cd45rc-antibody-for-rheumatoid-arthritis 2025-05-07T10:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-primary-sclerosing-cholangitis-dr-falk-pharma-s-norucholic-acid-shows-positive-phase-3-results 2025-05-07T10:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-primary-sclerosing-cholangitis-dr-falk-pharma-s-norucholic-acid-shows-positive-phase-3-results 2025-05-07T10:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/bulevirtide-shows-durable-response-in-chronic-hepatitis-delta-virus-after-treatment-cessation 2025-05-07T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bulevirtide-shows-durable-response-in-chronic-hepatitis-delta-virus-after-treatment-cessation 2025-05-07T10:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/astraveus-partners-with-necstgen-to-revolutionize-car-t-manufacturing-with-microfluidic-technology 2025-05-07T10:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astraveus-partners-with-necstgen-to-revolutionize-car-t-manufacturing-with-microfluidic-technology 2025-05-07T10:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/chop-researchers-propose-alk-inhibitors-as-new-standard-for-hereditary-neuroblastoma 2025-05-07T10:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chop-researchers-propose-alk-inhibitors-as-new-standard-for-hereditary-neuroblastoma 2025-05-07T10:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/gemvax-s-gv1001-receives-fda-fast-track-designation-and-korean-therapeutic-use-approval-for-progressive-supranuclear-palsy 2025-05-07T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gemvax-s-gv1001-receives-fda-fast-track-designation-and-korean-therapeutic-use-approval-for-progressive-supranuclear-palsy 2025-05-07T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/marea-s-mar-001-shows-promising-lipid-lowering-results-in-phase-2a-cardiovascular-study 2025-05-07T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marea-s-mar-001-shows-promising-lipid-lowering-results-in-phase-2a-cardiovascular-study 2025-05-07T10:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/markel-launches-global-clinical-trials-insurance-solution-to-accelerate-research-timelines 2025-05-07T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/markel-launches-global-clinical-trials-insurance-solution-to-accelerate-research-timelines 2025-05-07T09:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/fastwave-medical-receives-irb-approval-for-novel-coronary-laser-intravascular-lithotripsy-system 2025-05-07T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fastwave-medical-receives-irb-approval-for-novel-coronary-laser-intravascular-lithotripsy-system 2025-05-07T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/shingles-vaccine-reduces-cardiovascular-risk-by-23-for-up-to-eight-years-study-finds 2025-05-07T07:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shingles-vaccine-reduces-cardiovascular-risk-by-23-for-up-to-eight-years-study-finds 2025-05-07T07:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/beacon-therapeutics-reports-promising-phase-2-data-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-05-07T07:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beacon-therapeutics-reports-promising-phase-2-data-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-05-07T07:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/vinay-prasad-s-appointment-to-lead-fda-s-cber-signals-potential-shift-in-regulatory-standards 2025-05-07T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vinay-prasad-s-appointment-to-lead-fda-s-cber-signals-potential-shift-in-regulatory-standards 2025-05-07T07:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-elecsys-pro-c3-test-for-precise-liver-fibrosis-assessment-in-masld-patients 2025-05-07T07:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-elecsys-pro-c3-test-for-precise-liver-fibrosis-assessment-in-masld-patients 2025-05-07T07:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-partners-with-anemocyte-to-advance-cell-based-cancer-therapy-manufacturing 2025-05-07T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-science-partners-with-anemocyte-to-advance-cell-based-cancer-therapy-manufacturing 2025-05-07T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-to-present-promising-data-on-anx007-s-neuroprotective-effects-in-geographic-atrophy-at-major-ophthalmology-conferences 2025-05-07T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-to-present-promising-data-on-anx007-s-neuroprotective-effects-in-geographic-atrophy-at-major-ophthalmology-conferences 2025-05-07T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e-therapeutics-etx-312-shows-promise-as-disease-modifying-mash-treatment-in-preclinical-studies 2025-05-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/e-therapeutics-etx-312-shows-promise-as-disease-modifying-mash-treatment-in-preclinical-studies 2025-05-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/koala-health-raises-20-million-series-b-to-transform-pet-medication-delivery-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/koala-health-raises-20-million-series-b-to-transform-pet-medication-delivery-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/viverita-therapeutics-partners-with-boehringer-ingelheim-to-discover-novel-cancer-targets-using-in-vivo-crispr-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viverita-therapeutics-partners-with-boehringer-ingelheim-to-discover-novel-cancer-targets-using-in-vivo-crispr-platform 2025-05-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aav-vector-production-challenges-drive-innovation-in-gene-therapy-manufacturing 2025-05-07T04:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aav-vector-production-challenges-drive-innovation-in-gene-therapy-manufacturing 2025-05-07T04:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-system-atrophy-pipeline-shows-promise-with-22-therapies-in-development-as-fda-grants-fast-track-designations 2025-05-07T04:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-system-atrophy-pipeline-shows-promise-with-22-therapies-in-development-as-fda-grants-fast-track-designations 2025-05-07T04:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioaegis-therapeutics-advances-global-phase-2b-trial-of-gelsolin-therapy-for-ards-treatment 2025-05-07T04:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioaegis-therapeutics-advances-global-phase-2b-trial-of-gelsolin-therapy-for-ards-treatment 2025-05-07T04:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/mana-bio-unveils-ai-driven-advances-in-rna-delivery-at-asgct-2025 2025-05-07T04:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mana-bio-unveils-ai-driven-advances-in-rna-delivery-at-asgct-2025 2025-05-07T04:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardiothoracic-surgeon-emphasizes-human-resources-as-key-to-ai-driven-cardiovascular-care-transformation 2025-05-07T02:39:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiothoracic-surgeon-emphasizes-human-resources-as-key-to-ai-driven-cardiovascular-care-transformation 2025-05-07T02:39:42+00:00 hourly 0.9 https://trial.medpath.com/news/virion-therapeutics-vron-0200-shows-rapid-hbsag-declines-in-phase-1b-hepatitis-b-functional-cure-trial 2025-05-07T02:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virion-therapeutics-vron-0200-shows-rapid-hbsag-declines-in-phase-1b-hepatitis-b-functional-cure-trial 2025-05-07T02:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinuvel-advances-phase-iii-trial-for-vitiligo-treatment-with-scenesse-r-recruiting-over-200-patients 2025-05-07T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinuvel-advances-phase-iii-trial-for-vitiligo-treatment-with-scenesse-r-recruiting-over-200-patients 2025-05-07T01:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/recludix-unveils-first-in-class-btk-sh2-domain-inhibitor-with-superior-selectivity-for-chronic-spontaneous-urticaria 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recludix-unveils-first-in-class-btk-sh2-domain-inhibitor-with-superior-selectivity-for-chronic-spontaneous-urticaria 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapamycin-shows-promise-as-anti-aging-drug-matching-benefits-of-calorie-restriction-in-comprehensive-study 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapamycin-shows-promise-as-anti-aging-drug-matching-benefits-of-calorie-restriction-in-comprehensive-study 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vagus-nerve-stimulation-achieves-100-ptsd-diagnosis-loss-in-phase-1-trial 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vagus-nerve-stimulation-achieves-100-ptsd-diagnosis-loss-in-phase-1-trial 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-radiopharmaceuticals-summit-returns-to-europe-and-us-as-industry-momentum-builds 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-radiopharmaceuticals-summit-returns-to-europe-and-us-as-industry-momentum-builds 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/indian-origin-scientists-develop-weekly-injectable-for-parkinson-s-disease-treatment 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-origin-scientists-develop-weekly-injectable-for-parkinson-s-disease-treatment 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-discusses-columvi-combination-for-relapsed-or-refractory-dlbcl 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-discusses-columvi-combination-for-relapsed-or-refractory-dlbcl 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-secures-1-37-million-in-funding-for-cannabinoid-based-pain-management-research 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyus-life-sciences-secures-1-37-million-in-funding-for-cannabinoid-based-pain-management-research 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-beneficiaries-under-65-without-supplemental-coverage-face-significant-care-barriers 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-beneficiaries-under-65-without-supplemental-coverage-face-significant-care-barriers 2025-05-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-testing-advances-personalized-treatment-strategies-in-ovarian-cancer 2025-05-06T23:39:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-testing-advances-personalized-treatment-strategies-in-ovarian-cancer 2025-05-06T23:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/vasomune-to-present-late-breaking-data-on-av-001-s-protective-effects-against-covid-19-at-ats-conference 2025-05-06T23:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vasomune-to-present-late-breaking-data-on-av-001-s-protective-effects-against-covid-19-at-ats-conference 2025-05-06T23:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-unannounced-inspections-at-foreign-manufacturing-facilities-to-level-global-oversight 2025-05-06T22:35:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-unannounced-inspections-at-foreign-manufacturing-facilities-to-level-global-oversight 2025-05-06T22:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-reduces-radiotherapy-need-in-early-stage-endometrial-cancer 2025-05-06T22:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-profiling-reduces-radiotherapy-need-in-early-stage-endometrial-cancer 2025-05-06T22:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/brightheart-secures-third-fda-clearance-for-ai-powered-fetal-heart-ultrasound-technology 2025-05-06T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brightheart-secures-third-fda-clearance-for-ai-powered-fetal-heart-ultrasound-technology 2025-05-06T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-reports-strong-q1-2025-performance-with-898-million-in-revenue-advances-pipeline-with-zepzelca-snda-submission 2025-05-06T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-reports-strong-q1-2025-performance-with-898-million-in-revenue-advances-pipeline-with-zepzelca-snda-submission 2025-05-06T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-and-novelty-nobility-form-strategic-partnership-for-bispecific-antibody-development 2025-05-06T22:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-and-novelty-nobility-form-strategic-partnership-for-bispecific-antibody-development 2025-05-06T22:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/deerfield-management-raises-over-600m-for-third-biotech-innovation-fund 2025-05-06T19:39:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deerfield-management-raises-over-600m-for-third-biotech-innovation-fund 2025-05-06T19:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/elekta-unity-mr-linac-preserves-sexual-function-in-men-with-prostate-cancer-clinical-trial-shows 2025-05-06T19:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elekta-unity-mr-linac-preserves-sexual-function-in-men-with-prostate-cancer-clinical-trial-shows 2025-05-06T19:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-hemiclor-first-low-dose-chlorthalidone-tablet-for-hypertension-management 2025-05-06T19:38:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-hemiclor-first-low-dose-chlorthalidone-tablet-for-hypertension-management 2025-05-06T19:38:11+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-wins-federal-circuit-appeal-path-cleared-for-lumryz-development-in-idiopathic-hypersomnia 2025-05-06T19:38:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-wins-federal-circuit-appeal-path-cleared-for-lumryz-development-in-idiopathic-hypersomnia 2025-05-06T19:38:06+00:00 hourly 0.9 https://trial.medpath.com/news/adnoc-s-eur12-billion-covestro-acquisition-faces-eu-foreign-subsidy-investigation 2025-05-06T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adnoc-s-eur12-billion-covestro-acquisition-faces-eu-foreign-subsidy-investigation 2025-05-06T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/zivo-bioscience-partners-with-global-animal-health-leader-to-advance-algal-derived-immune-boosters-for-poultry-disease-prevention 2025-05-06T17:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zivo-bioscience-partners-with-global-animal-health-leader-to-advance-algal-derived-immune-boosters-for-poultry-disease-prevention 2025-05-06T17:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/tpg-acquires-35-stake-in-schott-poonawalla-for-300-million-strengthening-drug-delivery-innovation 2025-05-06T17:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tpg-acquires-35-stake-in-schott-poonawalla-for-300-million-strengthening-drug-delivery-innovation 2025-05-06T17:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/24-companies-advancing-hidradenitis-suppurativa-treatment-pipeline-with-novel-therapies 2025-05-06T16:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/24-companies-advancing-hidradenitis-suppurativa-treatment-pipeline-with-novel-therapies 2025-05-06T16:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-launches-phase-ii-trial-of-first-in-class-oral-treatment-for-geographic-atrophy 2025-05-06T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-launches-phase-ii-trial-of-first-in-class-oral-treatment-for-geographic-atrophy 2025-05-06T16:39:15+00:00 hourly 0.9 https://trial.medpath.com/news/priothera-appoints-dr-jens-hasskarl-as-chief-medical-officer-to-lead-phase-3-trial-of-mocravimod-for-acute-myeloid-leukemia 2025-05-06T16:38:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priothera-appoints-dr-jens-hasskarl-as-chief-medical-officer-to-lead-phase-3-trial-of-mocravimod-for-acute-myeloid-leukemia 2025-05-06T16:38:40+00:00 hourly 0.9 https://trial.medpath.com/news/fremanezumab-shows-dual-efficacy-in-treating-both-migraine-and-depression-in-landmark-trial 2025-05-06T16:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fremanezumab-shows-dual-efficacy-in-treating-both-migraine-and-depression-in-landmark-trial 2025-05-06T16:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-dtab-streamlines-drug-trial-approvals-notification-system-introduced-timelines-halved 2025-05-06T16:37:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-dtab-streamlines-drug-trial-approvals-notification-system-introduced-timelines-halved 2025-05-06T16:37:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-ideaya-s-novel-dll3-targeting-antibody-drug-conjugate-ide849-for-solid-tumors 2025-05-06T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-ideaya-s-novel-dll3-targeting-antibody-drug-conjugate-ide849-for-solid-tumors 2025-05-06T16:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-lurasidone-for-schizophrenia-in-canadian-market 2025-05-06T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-lurasidone-for-schizophrenia-in-canadian-market 2025-05-06T16:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/clario-strengthens-neuroscience-clinical-trial-capabilities-with-acquisition-of-wcg-s-ecoa-business 2025-05-06T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clario-strengthens-neuroscience-clinical-trial-capabilities-with-acquisition-of-wcg-s-ecoa-business 2025-05-06T16:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-enrolls-first-patient-in-groundbreaking-iomab-act-car-t-conditioning-trial 2025-05-06T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinium-enrolls-first-patient-in-groundbreaking-iomab-act-car-t-conditioning-trial 2025-05-06T16:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-oral-glp-1-for-weight-management-as-q2-2025-brings-major-endocrinology-advances 2025-05-06T15:00:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-oral-glp-1-for-weight-management-as-q2-2025-brings-major-endocrinology-advances 2025-05-06T15:00:05+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-therapeutics-secures-12-5m-investment-to-advance-novel-epidermolysis-bullosa-treatment 2025-05-06T14:52:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-therapeutics-secures-12-5m-investment-to-advance-novel-epidermolysis-bullosa-treatment 2025-05-06T14:52:24+00:00 hourly 0.9 https://trial.medpath.com/news/zetagen-therapeutics-completes-enrollment-in-phase-2a-trial-for-novel-metastatic-breast-cancer-bone-lesion-treatment 2025-05-06T14:38:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zetagen-therapeutics-completes-enrollment-in-phase-2a-trial-for-novel-metastatic-breast-cancer-bone-lesion-treatment 2025-05-06T14:38:38+00:00 hourly 0.9 https://trial.medpath.com/news/heron-therapeutics-settles-patent-litigation-with-mylan-for-cinvanti-and-aponvie 2025-05-06T14:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heron-therapeutics-settles-patent-litigation-with-mylan-for-cinvanti-and-aponvie 2025-05-06T14:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-and-alchemab-forge-415m-partnership-for-novel-als-antibody-therapy 2025-05-06T14:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-and-alchemab-forge-415m-partnership-for-novel-als-antibody-therapy 2025-05-06T14:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-to-present-comprehensive-analyses-of-ohtuvayre-in-copd-at-ats-2025 2025-05-06T13:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-pharma-to-present-comprehensive-analyses-of-ohtuvayre-in-copd-at-ats-2025 2025-05-06T13:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-shift-in-c3g-treatment-new-clinical-criteria-for-therapy-escalation-and-emerging-complement-inhibitors 2025-05-06T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-shift-in-c3g-treatment-new-clinical-criteria-for-therapy-escalation-and-emerging-complement-inhibitors 2025-05-06T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/livekidney-initiates-phase-i-iia-trial-of-novel-cell-therapy-lk-sc001-for-lupus-nephritis 2025-05-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livekidney-initiates-phase-i-iia-trial-of-novel-cell-therapy-lk-sc001-for-lupus-nephritis 2025-05-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/rapidpulse-initiates-patient-enrollment-in-pivotal-ide-study-for-novel-ischemic-stroke-treatment 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapidpulse-initiates-patient-enrollment-in-pivotal-ide-study-for-novel-ischemic-stroke-treatment 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/safe-life-expands-european-aed-market-presence-through-swiss-acquisition-of-resqshock 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/safe-life-expands-european-aed-market-presence-through-swiss-acquisition-of-resqshock 2025-05-06T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/khondrion-secures-eur5-million-government-credit-to-advance-phase-3-trial-for-rare-mitochondrial-disease 2025-05-06T10:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khondrion-secures-eur5-million-government-credit-to-advance-phase-3-trial-for-rare-mitochondrial-disease 2025-05-06T10:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-based-immunotherapy-achieves-complete-remission-in-terminal-colon-cancer-patient 2025-05-06T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-based-immunotherapy-achieves-complete-remission-in-terminal-colon-cancer-patient 2025-05-06T10:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/blocking-nitrosylation-a-breakthrough-strategy-for-treating-aggressive-nras-melanoma 2025-05-06T10:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blocking-nitrosylation-a-breakthrough-strategy-for-treating-aggressive-nras-melanoma 2025-05-06T10:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-givinostat-for-polycythemia-vera-treatment 2025-05-06T10:34:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-givinostat-for-polycythemia-vera-treatment 2025-05-06T10:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-s-bengaluru-facility-receives-ema-gmp-certification-for-advanced-drug-delivery-systems 2025-05-06T10:34:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-s-bengaluru-facility-receives-ema-gmp-certification-for-advanced-drug-delivery-systems 2025-05-06T10:34:12+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-s-ameluz-secures-patent-extension-to-2043-targets-5-7b-acne-market 2025-05-06T10:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-s-ameluz-secures-patent-extension-to-2043-targets-5-7b-acne-market 2025-05-06T10:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/novaremed-completes-enrollment-in-nih-sponsored-phase-2b-trial-of-non-opioid-nrd-e1-for-diabetic-neuropathy-pain 2025-05-06T10:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novaremed-completes-enrollment-in-nih-sponsored-phase-2b-trial-of-non-opioid-nrd-e1-for-diabetic-neuropathy-pain 2025-05-06T10:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/hovione-and-firstgene-partner-to-develop-novel-gene-therapy-for-liver-cancer 2025-05-06T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hovione-and-firstgene-partner-to-develop-novel-gene-therapy-for-liver-cancer 2025-05-06T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/viralgen-and-trogenix-partner-to-accelerate-aav-gene-therapy-for-glioblastoma 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viralgen-and-trogenix-partner-to-accelerate-aav-gene-therapy-for-glioblastoma 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dianthus-therapeutics-completes-enrollment-in-phase-2-magic-trial-for-generalized-myasthenia-gravis-treatment 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dianthus-therapeutics-completes-enrollment-in-phase-2-magic-trial-for-generalized-myasthenia-gravis-treatment 2025-05-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/datavant-and-boehringer-ingelheim-expand-real-world-evidence-partnership-across-75-clinical-trials 2025-05-06T08:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datavant-and-boehringer-ingelheim-expand-real-world-evidence-partnership-across-75-clinical-trials 2025-05-06T08:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/catheter-precision-acquires-cardionomic-s-heart-failure-technology-for-novel-neuromodulation-therapy 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catheter-precision-acquires-cardionomic-s-heart-failure-technology-for-novel-neuromodulation-therapy 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/safeheal-secures-eur35-million-in-series-c-funding-to-advance-colovac-device-for-colorectal-surgery 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/safeheal-secures-eur35-million-in-series-c-funding-to-advance-colovac-device-for-colorectal-surgery 2025-05-06T08:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-reports-strong-q1-2025-results-with-8-revenue-growth-projection-amid-pipeline-advancements 2025-05-06T07:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-reports-strong-q1-2025-results-with-8-revenue-growth-projection-amid-pipeline-advancements 2025-05-06T07:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-expands-r-d-and-manufacturing-footprint-in-florida-to-support-inhaled-therapeutics-pipeline 2025-05-06T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transpire-bio-expands-r-d-and-manufacturing-footprint-in-florida-to-support-inhaled-therapeutics-pipeline 2025-05-06T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/route-92-medical-wins-patent-litigation-settlement-q-apel-permanently-removes-competing-neurovascular-product 2025-05-06T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/route-92-medical-wins-patent-litigation-settlement-q-apel-permanently-removes-competing-neurovascular-product 2025-05-06T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-and-takeda-strengthen-partnership-with-improved-terms-for-covid-19-vaccine-in-japan 2025-05-06T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-and-takeda-strengthen-partnership-with-improved-terms-for-covid-19-vaccine-in-japan 2025-05-06T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-will-ask-outside-experts-to-review-capricor-s-therapy-for-duchenne-muscular-dystrophy 2025-05-06T05:36:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-will-ask-outside-experts-to-review-capricor-s-therapy-for-duchenne-muscular-dystrophy 2025-05-06T05:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-secures-new-u-s-patent-for-tamp-therapy-platform-strengthening-ip-portfolio-for-targeted-cancer-treatment 2025-05-06T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-secures-new-u-s-patent-for-tamp-therapy-platform-strengthening-ip-portfolio-for-targeted-cancer-treatment 2025-05-06T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ide-for-ecm-therapeutics-novel-hydrogel-treatment-for-anorectal-fistulas 2025-05-06T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ide-for-ecm-therapeutics-novel-hydrogel-treatment-for-anorectal-fistulas 2025-05-06T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-s-aurora-spect-ct-and-clarify-dl-receive-fda-clearance-advancing-nuclear-medicine-imaging 2025-05-06T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-s-aurora-spect-ct-and-clarify-dl-receive-fda-clearance-advancing-nuclear-medicine-imaging 2025-05-06T04:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ritedose-s-albuterol-sulfate-inhalation-solution-amid-national-shortage 2025-05-06T04:40:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ritedose-s-albuterol-sulfate-inhalation-solution-amid-national-shortage 2025-05-06T04:40:26+00:00 hourly 0.9 https://trial.medpath.com/news/fangzhou-expands-access-to-breakthrough-leukemia-treatment-with-ponatinib-launch-in-china 2025-05-06T04:40:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fangzhou-expands-access-to-breakthrough-leukemia-treatment-with-ponatinib-launch-in-china 2025-05-06T04:40:20+00:00 hourly 0.9 https://trial.medpath.com/news/beijing-tide-s-first-in-class-at2r-antagonist-trd205-enters-phase-ii-trials-for-chronic-post-surgical-pain 2025-05-06T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beijing-tide-s-first-in-class-at2r-antagonist-trd205-enters-phase-ii-trials-for-chronic-post-surgical-pain 2025-05-06T04:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-naxtarubicin-as-international-generic-name-for-moleculin-s-cancer-drug-annamycin 2025-05-06T04:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-naxtarubicin-as-international-generic-name-for-moleculin-s-cancer-drug-annamycin 2025-05-06T04:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/ptc518-shows-promise-in-huntington-s-disease-phase-2-trial-meets-primary-endpoint 2025-05-06T04:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc518-shows-promise-in-huntington-s-disease-phase-2-trial-meets-primary-endpoint 2025-05-06T04:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-clinical-trial-system-shutdown-shocks-medical-research-community 2025-05-06T04:38:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-clinical-trial-system-shutdown-shocks-medical-research-community 2025-05-06T04:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/daridorexant-shows-promising-results-in-improving-night-to-day-transition-for-insomnia-patients 2025-05-06T04:38:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daridorexant-shows-promising-results-in-improving-night-to-day-transition-for-insomnia-patients 2025-05-06T04:38:36+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-s-efdamrofusp-alfa-shows-promising-results-for-neovascular-amd-with-extended-dosing-potential 2025-05-06T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-s-efdamrofusp-alfa-shows-promising-results-for-neovascular-amd-with-extended-dosing-potential 2025-05-06T04:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/jnj-1900-shows-promise-in-phase-1-trial-for-advanced-pancreatic-cancer 2025-05-06T04:38:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jnj-1900-shows-promise-in-phase-1-trial-for-advanced-pancreatic-cancer 2025-05-06T04:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/scribe-therapeutics-to-present-novel-crispr-based-gene-therapy-data-for-duchenne-muscular-dystrophy-at-asgct-2025 2025-05-06T04:36:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scribe-therapeutics-to-present-novel-crispr-based-gene-therapy-data-for-duchenne-muscular-dystrophy-at-asgct-2025 2025-05-06T04:36:43+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-s-light-activated-ruvidar-shows-promising-results-in-bcg-unresponsive-bladder-cancer-clinical-trial 2025-05-06T04:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-s-light-activated-ruvidar-shows-promising-results-in-bcg-unresponsive-bladder-cancer-clinical-trial 2025-05-06T04:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapies-drive-growth-in-adult-t-cell-leukemia-lymphoma-market-despite-access-challenges 2025-05-06T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapies-drive-growth-in-adult-t-cell-leukemia-lymphoma-market-despite-access-challenges 2025-05-06T04:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/integra-therapeutics-and-factor-bioscience-showcase-advanced-gene-editing-technologies-for-car-t-cell-therapies-at-asgct-2025 2025-05-06T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integra-therapeutics-and-factor-bioscience-showcase-advanced-gene-editing-technologies-for-car-t-cell-therapies-at-asgct-2025 2025-05-06T04:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/genprex-secures-exclusive-license-for-reqorsa-gene-therapy-in-glioblastoma-treatment 2025-05-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genprex-secures-exclusive-license-for-reqorsa-gene-therapy-in-glioblastoma-treatment 2025-05-06T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-partners-with-dcai-to-accelerate-brain-disorder-drug-discovery-using-gefion-ai-supercomputer 2025-05-06T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-partners-with-dcai-to-accelerate-brain-disorder-drug-discovery-using-gefion-ai-supercomputer 2025-05-06T02:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/inbrain-neuroelectronics-secures-eur4-million-grant-to-advance-graphene-based-brain-computer-interface-technology 2025-05-06T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inbrain-neuroelectronics-secures-eur4-million-grant-to-advance-graphene-based-brain-computer-interface-technology 2025-05-06T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/repose-study-confirms-real-world-efficacy-of-higher-dose-onabotulinumtoxina-for-chronic-migraine 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repose-study-confirms-real-world-efficacy-of-higher-dose-onabotulinumtoxina-for-chronic-migraine 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbd-life-sciences-expands-global-footprint-with-strategic-manufacturing-partnerships-in-colombia-and-u-s 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbd-life-sciences-expands-global-footprint-with-strategic-manufacturing-partnerships-in-colombia-and-u-s 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dynamic-biomarkers-show-promise-for-predicting-immune-checkpoint-inhibitor-response-in-cancer-patients 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynamic-biomarkers-show-promise-for-predicting-immune-checkpoint-inhibitor-response-in-cancer-patients 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agendia-s-blueprint-test-shows-promise-in-identifying-chemotherapy-responsive-breast-cancer-subtypes 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agendia-s-blueprint-test-shows-promise-in-identifying-chemotherapy-responsive-breast-cancer-subtypes 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ousia-pharma-secures-seed-financing-from-omega-funds-to-develop-novel-obesity-treatment-targeting-nmda-receptors 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ousia-pharma-secures-seed-financing-from-omega-funds-to-develop-novel-obesity-treatment-targeting-nmda-receptors 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-selected-for-korea-s-national-avian-influenza-vaccine-development-program 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-selected-for-korea-s-national-avian-influenza-vaccine-development-program 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-partners-with-creyon-bio-in-1b-deal-to-develop-ai-designed-rna-therapies 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-partners-with-creyon-bio-in-1b-deal-to-develop-ai-designed-rna-therapies 2025-05-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/endospan-s-nexus-aortic-arch-stent-graft-shows-promising-30-day-results-in-fda-triomphe-trial 2025-05-05T20:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endospan-s-nexus-aortic-arch-stent-graft-shows-promising-30-day-results-in-fda-triomphe-trial 2025-05-05T20:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/kane-biotech-secures-2-2-million-through-private-placement-and-insider-loan-to-advance-biofilm-disrupting-wound-care-technology 2025-05-05T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kane-biotech-secures-2-2-million-through-private-placement-and-insider-loan-to-advance-biofilm-disrupting-wound-care-technology 2025-05-05T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-jersey-transforms-cancer-care-landscape-with-first-freestanding-cancer-hospital 2025-05-05T15:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-jersey-transforms-cancer-care-landscape-with-first-freestanding-cancer-hospital 2025-05-05T15:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/ferring-s-iris-study-demonstrates-improved-ivf-outcomes-with-individualized-follitropin-delta-dosing-in-indian-patients 2025-05-05T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferring-s-iris-study-demonstrates-improved-ivf-outcomes-with-individualized-follitropin-delta-dosing-in-indian-patients 2025-05-05T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cannabix-technologies-secures-nhtsa-approval-and-manufacturing-partnership-for-breathlogix-alcohol-screening-device 2025-05-05T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabix-technologies-secures-nhtsa-approval-and-manufacturing-partnership-for-breathlogix-alcohol-screening-device 2025-05-05T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacy-industry-fellowships-a-critical-pathway-for-pharmd-graduates-career-development 2025-05-05T14:14:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacy-industry-fellowships-a-critical-pathway-for-pharmd-graduates-career-development 2025-05-05T14:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-presents-long-term-data-on-rare-endocrine-disease-therapies-at-major-medical-conferences 2025-05-05T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-presents-long-term-data-on-rare-endocrine-disease-therapies-at-major-medical-conferences 2025-05-05T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneration-biomedical-reports-promising-phase-1-results-for-direct-brain-injection-of-stem-cells-in-alzheimer-s-disease 2025-05-05T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneration-biomedical-reports-promising-phase-1-results-for-direct-brain-injection-of-stem-cells-in-alzheimer-s-disease 2025-05-05T12:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/texas-girl-to-make-medical-history-with-first-ever-treatment-for-rare-nars1-genetic-disorder 2025-05-05T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/texas-girl-to-make-medical-history-with-first-ever-treatment-for-rare-nars1-genetic-disorder 2025-05-05T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-phase-1-trial-combines-tagraxofusp-and-pacritinib-for-treatment-resistant-myelofibrosis 2025-05-05T09:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-phase-1-trial-combines-tagraxofusp-and-pacritinib-for-treatment-resistant-myelofibrosis 2025-05-05T09:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/autonomix-medical-reports-significant-pain-reduction-in-pancreatic-cancer-patients-with-novel-nerve-ablation-technique 2025-05-05T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomix-medical-reports-significant-pain-reduction-in-pancreatic-cancer-patients-with-novel-nerve-ablation-technique 2025-05-05T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/ontada-presents-14-real-world-evidence-studies-at-ispor-2025-to-advance-cancer-care-research 2025-05-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontada-presents-14-real-world-evidence-studies-at-ispor-2025-to-advance-cancer-care-research 2025-05-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-target-alzheimer-s-vaccine-duvax-receives-3-million-nih-grant-for-phase-1-trials 2025-05-05T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-target-alzheimer-s-vaccine-duvax-receives-3-million-nih-grant-for-phase-1-trials 2025-05-05T07:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/palatin-s-pl9588-shows-promise-as-dual-action-glaucoma-therapy-with-neuroprotective-effects 2025-05-05T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palatin-s-pl9588-shows-promise-as-dual-action-glaucoma-therapy-with-neuroprotective-effects 2025-05-05T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-advances-janx007-to-phase-1b-trials-for-prostate-cancer-with-promising-survival-data 2025-05-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-advances-janx007-to-phase-1b-trials-for-prostate-cancer-with-promising-survival-data 2025-05-05T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/targeted-therapies-transform-biliary-tract-cancer-treatment-as-her2-directed-agents-gain-fda-approval 2025-05-05T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeted-therapies-transform-biliary-tract-cancer-treatment-as-her2-directed-agents-gain-fda-approval 2025-05-05T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/brain-cancer-canada-awards-170k-for-two-glioblastoma-research-projects-targeting-treatment-resistance 2025-05-05T05:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-cancer-canada-awards-170k-for-two-glioblastoma-research-projects-targeting-treatment-resistance 2025-05-05T05:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-solutions-secures-eurasian-patent-approval-for-sublingual-ms-treatment-technology 2025-05-05T03:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionxt-solutions-secures-eurasian-patent-approval-for-sublingual-ms-treatment-technology 2025-05-05T03:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-industries-reports-phase-2-success-for-oral-obesity-drug-na-931-at-ada-2025 2025-05-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-industries-reports-phase-2-success-for-oral-obesity-drug-na-931-at-ada-2025 2025-05-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-therapy-shows-promise-in-first-human-trial-for-advanced-gi-cancers 2025-05-04T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-therapy-shows-promise-in-first-human-trial-for-advanced-gi-cancers 2025-05-04T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-slash-drug-approval-times-by-half-with-new-streamlined-procedures 2025-05-04T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-slash-drug-approval-times-by-half-with-new-streamlined-procedures 2025-05-04T16:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-quikclot-control-hemostatic-device-indications-to-all-bleeding-grades 2025-05-04T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-quikclot-control-hemostatic-device-indications-to-all-bleeding-grades 2025-05-04T16:33:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-nutshell-therapeutics-novel-p53-y220c-reactivator-nts071 2025-05-04T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-nutshell-therapeutics-novel-p53-y220c-reactivator-nts071 2025-05-04T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/home-administration-of-long-acting-hiv-injectable-therapy-proves-safe-and-effective-as-clinic-treatment 2025-05-04T04:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/home-administration-of-long-acting-hiv-injectable-therapy-proves-safe-and-effective-as-clinic-treatment 2025-05-04T04:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-novel-immune-modulatory-cancer-vaccine-shows-promise-in-phase-3-trials 2025-05-04T04:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-novel-immune-modulatory-cancer-vaccine-shows-promise-in-phase-3-trials 2025-05-04T04:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-shows-promise-for-hepatitis-b-functional-cure-with-100-sustained-seroconversion-in-preclinical-study 2025-05-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapy-shows-promise-for-hepatitis-b-functional-cure-with-100-sustained-seroconversion-in-preclinical-study 2025-05-04T01:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/district-court-dismisses-united-therapeutics-dispute-against-liquidia-in-patent-litigation 2025-05-03T20:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/district-court-dismisses-united-therapeutics-dispute-against-liquidia-in-patent-litigation 2025-05-03T20:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-hyderabad-and-krismo-biosciences-partner-to-develop-novel-therapies-for-inflammatory-diseases-and-viral-infections 2025-05-03T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-hyderabad-and-krismo-biosciences-partner-to-develop-novel-therapies-for-inflammatory-diseases-and-viral-infections 2025-05-03T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/tae-life-sciences-and-ohio-state-university-partner-to-advance-boron-neutron-capture-therapy-for-cancer-treatment 2025-05-03T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tae-life-sciences-and-ohio-state-university-partner-to-advance-boron-neutron-capture-therapy-for-cancer-treatment 2025-05-03T16:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/complicated-urinary-tract-infection-pipeline-shows-robust-development-with-12-companies-advancing-novel-therapies 2025-05-03T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/complicated-urinary-tract-infection-pipeline-shows-robust-development-with-12-companies-advancing-novel-therapies 2025-05-03T16:35:30+00:00 hourly 0.9 https://trial.medpath.com/news/risankizumab-and-guselkumab-show-comparable-efficacy-in-real-world-psoriasis-treatment-over-one-year 2025-05-03T16:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risankizumab-and-guselkumab-show-comparable-efficacy-in-real-world-psoriasis-treatment-over-one-year 2025-05-03T16:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-ivonescimab-shows-promising-results-in-phase-3-nsclc-trial 2025-05-03T13:35:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-ivonescimab-shows-promising-results-in-phase-3-nsclc-trial 2025-05-03T13:35:10+00:00 hourly 0.9 https://trial.medpath.com/news/tissuecypher-test-shows-promise-in-identifying-barrett-s-esophagus-patients-at-risk-for-esophageal-cancer 2025-05-03T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissuecypher-test-shows-promise-in-identifying-barrett-s-esophagus-patients-at-risk-for-esophageal-cancer 2025-05-03T13:35:05+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-cuts-workforce-by-45-following-termination-of-idiopathic-pulmonary-fibrosis-trial 2025-05-03T13:35:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-cuts-workforce-by-45-following-termination-of-idiopathic-pulmonary-fibrosis-trial 2025-05-03T13:35:01+00:00 hourly 0.9 https://trial.medpath.com/news/novel-smart-capsule-technology-could-revolutionize-multi-medication-regimens 2025-05-03T11:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-smart-capsule-technology-could-revolutionize-multi-medication-regimens 2025-05-03T11:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-pinworm-drug-shows-promise-against-deadly-merkel-cell-carcinoma 2025-05-03T10:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-pinworm-drug-shows-promise-against-deadly-merkel-cell-carcinoma 2025-05-03T10:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-universal-antivenom-developed-using-blood-of-man-bitten-200-times 2025-05-03T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-universal-antivenom-developed-using-blood-of-man-bitten-200-times 2025-05-03T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/zucara-therapeutics-secures-25m-series-b-funding-to-advance-first-in-class-hypoglycemia-prevention-therapy 2025-05-03T07:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zucara-therapeutics-secures-25m-series-b-funding-to-advance-first-in-class-hypoglycemia-prevention-therapy 2025-05-03T07:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/faricimab-shows-superior-fluid-reduction-and-sustained-efficacy-in-wet-amd-through-3-year-data 2025-05-03T07:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faricimab-shows-superior-fluid-reduction-and-sustained-efficacy-in-wet-amd-through-3-year-data 2025-05-03T07:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-treatment-landscape-for-egfr-mutant-nsclc-managing-resistance-and-optimizing-therapy-sequence 2025-05-03T04:39:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-treatment-landscape-for-egfr-mutant-nsclc-managing-resistance-and-optimizing-therapy-sequence 2025-05-03T04:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/immuneoncia-therapeutics-raises-24m-in-successful-kosdaq-ipo-for-cancer-drug-development 2025-05-03T01:35:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneoncia-therapeutics-raises-24m-in-successful-kosdaq-ipo-for-cancer-drug-development 2025-05-03T01:35:57+00:00 hourly 0.9 https://trial.medpath.com/news/court-dismisses-united-therapeutics-challenge-against-liquidia-s-yutrepia-clearing-path-for-may-launch 2025-05-03T01:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/court-dismisses-united-therapeutics-challenge-against-liquidia-s-yutrepia-clearing-path-for-may-launch 2025-05-03T01:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/edwards-lifesciences-receives-fda-approval-for-tavr-therapy-in-asymptomatic-severe-aortic-stenosis 2025-05-02T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edwards-lifesciences-receives-fda-approval-for-tavr-therapy-in-asymptomatic-severe-aortic-stenosis 2025-05-02T22:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-partners-with-epic-to-integrate-freestyle-libre-cgm-data-into-electronic-health-records 2025-05-02T20:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-partners-with-epic-to-integrate-freestyle-libre-cgm-data-into-electronic-health-records 2025-05-02T20:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-partners-with-roosterbio-to-accelerate-cell-and-exosome-therapy-development 2025-05-02T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-partners-with-roosterbio-to-accelerate-cell-and-exosome-therapy-development 2025-05-02T20:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-plans-fda-submission-for-epcoritamab-combination-therapy-in-relapsed-follicular-lymphoma 2025-05-02T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-plans-fda-submission-for-epcoritamab-combination-therapy-in-relapsed-follicular-lymphoma 2025-05-02T19:35:20+00:00 hourly 0.9 https://trial.medpath.com/news/turn-therapeutics-achieves-breakthrough-in-room-temperature-vaccine-stability 2025-05-02T19:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/turn-therapeutics-achieves-breakthrough-in-room-temperature-vaccine-stability 2025-05-02T19:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-clinical-trial-results-accurately-predict-real-world-benefits-of-prostate-cancer-therapies 2025-05-02T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-clinical-trial-results-accurately-predict-real-world-benefits-of-prostate-cancer-therapies 2025-05-02T19:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-stelara-biosimilar-generates-150-million-in-first-quarter-highlighting-biosimilar-strategy-success 2025-05-02T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-stelara-biosimilar-generates-150-million-in-first-quarter-highlighting-biosimilar-strategy-success 2025-05-02T16:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/sohm-recruits-car-t-expert-dr-leonardo-mirandola-to-advance-novel-gene-editing-platform-toward-clinical-trials 2025-05-02T16:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sohm-recruits-car-t-expert-dr-leonardo-mirandola-to-advance-novel-gene-editing-platform-toward-clinical-trials 2025-05-02T16:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-ticagrelor-tablets-to-reduce-cardiovascular-risks 2025-05-02T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-receives-fda-approval-for-generic-ticagrelor-tablets-to-reduce-cardiovascular-risks 2025-05-02T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-drug-trial-shows-life-changing-results-for-children-with-dravet-syndrome 2025-05-02T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-drug-trial-shows-life-changing-results-for-children-with-dravet-syndrome 2025-05-02T16:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/novel-in-vivo-cd19-car-t-therapy-achieves-complete-remission-in-aggressive-dlbcl-without-lymphodepletion 2025-05-02T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-in-vivo-cd19-car-t-therapy-achieves-complete-remission-in-aggressive-dlbcl-without-lymphodepletion 2025-05-02T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-present-groundbreaking-respiratory-medicine-data-at-ats-2025-international-congress 2025-05-02T13:40:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-to-present-groundbreaking-respiratory-medicine-data-at-ats-2025-international-congress 2025-05-02T13:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-denies-cytosorbents-de-novo-request-for-drugsorb-atr-blood-purification-device 2025-05-02T13:40:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-denies-cytosorbents-de-novo-request-for-drugsorb-atr-blood-purification-device 2025-05-02T13:40:42+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-phase-1-trial-of-kh658-gene-therapy-for-wet-amd 2025-05-02T13:39:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-1-trial-of-kh658-gene-therapy-for-wet-amd 2025-05-02T13:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/cour-pharma-initiates-cnp-103-clinical-trial-for-newly-diagnosed-type-1-diabetes-patients 2025-05-02T13:27:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cour-pharma-initiates-cnp-103-clinical-trial-for-newly-diagnosed-type-1-diabetes-patients 2025-05-02T13:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-weight-loss-drug-wegovy-now-available-in-qatar-through-ebn-sina-medical-partnership 2025-05-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-weight-loss-drug-wegovy-now-available-in-qatar-through-ebn-sina-medical-partnership 2025-05-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-explores-pharmacy-based-weight-loss-injection-program-to-expand-access-at-prescription-prices 2025-05-02T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-explores-pharmacy-based-weight-loss-injection-program-to-expand-access-at-prescription-prices 2025-05-02T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/anavex-completes-enrollment-in-phase-2-trial-of-anavex-r-3-71-for-schizophrenia-treatment 2025-05-02T10:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anavex-completes-enrollment-in-phase-2-trial-of-anavex-r-3-71-for-schizophrenia-treatment 2025-05-02T10:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/shashvi-remedies-secures-rs-10-lakh-grant-for-breakthrough-breast-cancer-treatment-patent 2025-05-02T10:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shashvi-remedies-secures-rs-10-lakh-grant-for-breakthrough-breast-cancer-treatment-patent 2025-05-02T10:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/iq-ai-seeks-fda-breakthrough-therapy-designation-for-promising-glioblastoma-treatment 2025-05-02T10:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iq-ai-seeks-fda-breakthrough-therapy-designation-for-promising-glioblastoma-treatment 2025-05-02T10:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-shows-promise-in-reducing-knee-osteoarthritis-pain-in-overweight-patients 2025-05-02T10:05:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-shows-promise-in-reducing-knee-osteoarthritis-pain-in-overweight-patients 2025-05-02T10:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-reveals-significant-gender-disparities-in-health-outcomes 2025-05-02T10:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-reveals-significant-gender-disparities-in-health-outcomes 2025-05-02T10:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-breztri-shows-significant-improvement-in-phase-iii-asthma-trials 2025-05-02T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-breztri-shows-significant-improvement-in-phase-iii-asthma-trials 2025-05-02T07:35:26+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-reports-strong-global-demand-in-q1-2025-bolstering-long-term-growth-outlook 2025-05-02T07:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-reports-strong-global-demand-in-q1-2025-bolstering-long-term-growth-outlook 2025-05-02T07:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-advances-leqembi-treatment-with-subcutaneous-formulation-for-alzheimer-s-disease 2025-05-02T07:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-advances-leqembi-treatment-with-subcutaneous-formulation-for-alzheimer-s-disease 2025-05-02T07:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/endoform-natural-demonstrates-significant-healing-advantage-for-venous-leg-ulcers-in-large-real-world-study 2025-05-02T05:34:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endoform-natural-demonstrates-significant-healing-advantage-for-venous-leg-ulcers-in-large-real-world-study 2025-05-02T05:34:57+00:00 hourly 0.9 https://trial.medpath.com/news/aventus-thrombectomy-system-shows-promise-for-pulmonary-embolism-treatment-in-pivotal-trial 2025-05-02T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aventus-thrombectomy-system-shows-promise-for-pulmonary-embolism-treatment-in-pivotal-trial 2025-05-02T05:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/histoindex-secures-9-million-investment-to-advance-ai-powered-liver-disease-diagnostics 2025-05-02T04:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histoindex-secures-9-million-investment-to-advance-ai-powered-liver-disease-diagnostics 2025-05-02T04:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-emerges-as-key-solution-to-oncology-treatment-challenges 2025-05-02T04:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-emerges-as-key-solution-to-oncology-treatment-challenges 2025-05-02T04:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-pregnancy-risks-for-minority-women-with-cancer 2025-05-02T02:39:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-pregnancy-risks-for-minority-women-with-cancer 2025-05-02T02:39:41+00:00 hourly 0.9